

1 **Impact of disease-associated chromatin accessibility QTLs across immune cell types** 2 **and contexts**

3
4 Zepeng Mu^{1,2}, Haley E. Randolph^{1,3}, Raúl Aguirre-Gamboa⁴, Ellen Ketter⁵, Anne Dumaine⁴,
5 Veronica Locher⁶, Cary Brandolino⁴, Xuanyao Liu^{1,4,7}, Daniel E. Kaufmann^{8,9}, Luis B.
6 Barreiro^{1,4,6,7,10,†}, Yang I. Li^{1,4,7,10,†}

- 7
8 1. Committee on Genetics, Genomics & Systems Biology, University of Chicago, Chicago, IL, USA
9 2. Center for Data Sciences, Brigham and Women's Hospital, Harvard Medical School, Boston, MA,
10 USA
11 3. Department of Pediatrics, Columbia University Irving Medical Center, New York, NY
12 4. Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, USA
13 5. Committee on Microbiology, University of Chicago, Chicago, IL, USA
14 6. Committee on Immunology, University of Chicago, Chicago, IL, USA
15 7. Department of Human Genetics, Department of Medicine, University of Chicago, Chicago, IL,
16 USA
17 8. Division of Infectious Diseases, Department of Medicine, University Hospital and University of
18 Lausanne, Lausanne, Switzerland
19 9. Centre de Recherche du CHUM (CRCHUM) and Département de Médecine, Université de
20 Montréal, Montreal, QC, Canada
21 10. CZ Biohub Chicago, Chicago, IL, USA

22
23 † Corresponding authors

24 **Abstract**

25 Only a third of immune-associated loci from genome-wide association studies (GWAS) colocalize
26 with expression quantitative trait loci (eQTLs). To learn about causal genes and mechanisms at
27 the remaining loci, we created a unified single-cell chromatin accessibility (scATAC-seq) map in
28 peripheral blood comprising a total of 282,424 cells from 48 individuals. Clustering and topic
29 modeling of scATAC data identified discrete cell-types and continuous cell states, which helped
30 reveal disease-relevant cellular contexts, and allowed mapping of genetic effects on chromatin
31 accessibility across these contexts. We identified 37,390 chromatin accessibility QTLs (caQTL)
32 at 10% FDR across eight cell groups and observed extensive sharing of caQTLs across immune
33 cell contexts, finding that fewer than 20% of caQTLs are specific to a single cell type. Notably,
34 caQTLs colocalized with ~50% more GWAS loci compared to eQTLs, helping to nominate
35 putative causal genes for many unexplained loci. However, most GWAS-caQTL colocalizations
36 had no detectable downstream regulatory effects on gene expression levels in the same cell type.
37 We find evidence that the higher rates of colocalization between caQTLs and GWAS signals
38 reflect missing disease-relevant cellular contexts among existing eQTL studies. Thus, there
39 remains a pressing need for identifying disease-causing cellular contexts and for mapping gene
40 regulatory variation in these cells.

41
42

43 Introduction

44
45 A major goal in complex trait genomics is to understand the biological mechanisms of trait-
46 associated variants. To this end, a general approach has been to map molecular quantitative trait
47 loci (molQTLs) in one or more cell types or states, and then colocalize these molQTLs with GWAS
48 loci. GWAS loci colocalized with a molQTL are then often considered to be “explained”. To date,
49 molQTL of gene expression levels (eQTL) have been the focus of nearly all studies. Although
50 eQTLs have greatly improved our ability to identify genes and contexts that are impacted at many
51 GWAS loci, over half of GWAS signals remain unexplained for most complex traits¹.

52 Several groups have proposed that standard eQTL analyses from bulk samples generally
53 identify large, but unimportant genetic effects that are shared across many cell-types². Consistent
54 with this view, an analysis of GTEx eQTLs – the largest collection of eQTLs which covers over 55
55 human organs – revealed that *cis*-eQTLs only mediate ~11% of trait heritability on average³.
56 These findings are often interpreted to suggest that many GWAS variants function through cell-
57 type or context specific effects on gene regulation, motivating searches for eQTLs in specific cell-
58 types and contexts (i.e. cell subtypes/state, disease conditions) that may be more relevant to the
59 traits of interest. Indeed, several studies have now identified cell-type specific and highly transient
60 genetic effects on gene expression level that colocalize with association signals at GWAS loci⁴.
61 Even so, each study only contributes to a tiny number of additional colocalizations, raising
62 questions as to whether this approach is effective.

63 More recently, two studies mapped chromatin phenotypes QTLs (cQTLs) and found that
64 cQTLs substantially increased the fraction of GWAS loci that colocalizes with a molQTL^{5,6}. For
65 example, Aracena et al. (2024) found that chromatin accessibility QTLs (caQTLs) mediate roughly
66 twice as much trait heritability as eQTLs and colocalize with a larger fraction of GWAS loci
67 compared with eQTLs⁵. It is unclear why the rates of caQTLs colocalization are larger than that
68 of eQTLs, especially given that caQTLs must impact gene expression levels in their causal path
69 to influence human traits. Still, these findings, along with earlier reports that trait heritability
70 explained by eQTL SNPs (11%-14%)⁷ are generally smaller than that explained by SNPs in
71 enhancer and promoter regions (24%-79%)⁸, suggest that mapping QTLs for chromatin-level
72 phenotypes, such as chromatin accessibility QTLs (caQTLs), may help unravel genetic
73 mechanism of as yet unexplained GWAS loci.

74 To test this strategy, we built a unified map of single-cell chromatin accessibility (scATAC)
75 profiles in peripheral blood mononuclear cells (PBMCs) from 48 individuals enrolled in three
76 independent studies^{9,10}. We integrated these data and developed novel computational
77 approaches to map the impact of immune-related GWAS variants on chromatin accessibility
78 across immune cell-types, contexts, and cell trajectories. Remarkably, our caQTLs colocalize with
79 ~50% more GWAS loci on average than bulk eQTLs, helping us to examine the genetic regulatory
80 mechanisms that underpin previously uncolocalized immune disease-associated variants.
81 However, by analyzing these caQTLs with immune cell-type resolved eQTLs, we find that a
82 substantial fraction of caQTL effects do not have any eQTL effect in the corresponding cell-types
83 or contexts. We find that these can be predicted by the lack of enhancer-promoter interactions
84 and not by low statistical power. Thus, many genetic effects on chromatin accessibility are unlikely
85 to be functional in most cell-types. Notably, many immune GWAS loci that colocalizes with
86 caQTLs do not colocalize with an eQTL in any assayed cell-type, we interpret this to suggest that

87 there are many cellular contexts in which eQTL data are missing. Thus, our findings highlight the
88 need for expanding the catalog of eQTLs in cell-types and contexts that are more relevant to
89 disease.

90 Results

91 A harmonized map of chromatin accessibility in immune cells from 59 samples

92
93 To obtain a comprehensive map of chromatin accessibility in peripheral blood mononuclear cells
94 (PBMCs), we obtained and compared scATAC-seq data from participants with active COVID-19,
95 COVID-19 convalescent donors, and healthy controls (**Supplementary Table 1**). We collected
96 scATAC-seq data from the PBMCs of 25 unique donors, including 20 individuals hospitalized with
97 COVID-19 (both in active disease and a subset at a convalescent stage) as well as 5 healthy
98 controls. We obtained additional COVID-19 convalescent and healthy controls from two recently
99 published PBMC scATAC-seq datasets of similar quality (i.e., in terms of TSS read enrichment
100 and fragments per cell; **Extended Data Fig. 1a,b**). Specifically, we used 13 healthy control
101 samples from Bengali, et al.⁹ and 8 COVID-19 convalescent and 2 healthy control samples from
102 You, et al¹⁰ (**Fig. 1a**).

103 After filtering, integration using LSI, and reducedMNN harmonization, we retained 282,424
104 high-quality cells for further analysis (**Supplementary Table 1**). To obtain a cell-type resolved
105 map of chromatin accessibility, we first annotated cell-types using Azimuth¹¹ from previously
106 published COVID-19 scRNA-seq data¹² and transferred labels to our scATAC data. We also
107 identified 26 distinct cell clusters in this integrated dataset and confirmed that they are highly
108 consistent with Azimuth-annotated cell-types (**Extended Data Fig. 1c**). Our final annotation has
109 two levels of granularity: L1 annotations are later used for caQTL mapping, and contains seven
110 major immune cell-types, while L2 annotation are used for finer-grained interpretation, and
111 contains 21 cell-types/subtypes that are well represented in our data (**Fig. 1b-c**). We then called
112 a unified peak set consisting of 327,746 cis-regulatory elements (peaks)¹³. To confirm the quality
113 of these annotations, we assessed gene activity (GA) scores of marker genes in each cell-type
114 and observed high gene activity (GA) scores at known marker genes: *MS4A1* in B cells, *CD3E*
115 and *CD8A* in T cells, *NCR1* in NK cells, *S100A8* in monocytes, and *FLT3* in DC (**Fig. 1d**). We
116 also visualized genome browser tracks for markers in L2 cell annotations, and found patterns of
117 cell-type specific peaks that are broadly consistent with the annotated cell-types (**Fig. 1e-f**).

118
119 We compared the three donor groups (healthy, active COVID-19, and COVID-19 convalescent)
120 to identify differences in cell-type compositions. While the overall cell-type compositions were
121 similar among all individuals, there were a few notable exceptions. Two groups of COVID-19
122 patients had either expanded NK cell or monocyte populations, consistent with previous
123 reports^{10,14} (**Fig. 1g**). At the L2 annotation level, we found increased proportions of memory B
124 cells in COVID-19 patients compared to healthy controls (**Extended Data Fig. 1d**).

125
126 We next sought to obtain genotypes for scATAC-seq samples from the three harmonized datasets
127 in order to map genetic determinants of chromatin accessibility, i.e. quantitative trait loci (caQTL).
128 Even though one of the studies (You et al.) did not genotype individual donors, we reasoned that
129 we could approximate low-pass whole-genome sequencing (WGS) coverage by aggregating

130 single-cell reads from each individual and adapt GLIMPSE¹⁵ to accurately impute common
131 variants in these individuals. We tested this by comparing Minimac4-imputed SNPs from
132 genotyping arrays available from Benaglio et al. to the imputed SNPs from scATAC-seq using our
133 GLIMPSE workflow (**Methods**). We found that genotype dosages imputed from scATAC reads
134 and genotyping arrays were highly correlated across all reference minor-allele frequency (MAF)
135 bins (>91%, **Fig. 1h, Extended Data Fig. 1e-g**), indicating that imputed genotypes from scATAC-
136 reads are highly accurate and are not biased by allelic imbalance in chromatin accessibility. This
137 allowed us to merge genotype likelihood estimates from all three studies and to perform joint
138 imputation using GLIMPSE, resulting in a harmonized callset of 6.75 million high-quality SNPs for
139 caQTL mapping (**Extended Data Fig. 1h**).

140
141 Altogether, we constructed a map of accessible chromatin from 282,424 PBMCs from 59 samples
142 with high-quality, harmonized genotype information for all individuals, enabling fully-integrated
143 downstream analysis. Imputation using aggregated scATAC-seq reads offers high-quality
144 genotype information and our workflow (**Data availability**) can be easily adopted for future
145 population-scale scATAC studies.

147 **Topic analysis of chromatin accessibility defines cell-types and states programs**

148 Single-cell genomics data can capture gene expression in rare cell-types as well as transitional
149 cell states. However, typical single-cell data analysis aggregates cells into discrete clusters,
150 masking heterogeneity among cells within the same cluster. As an alternative to clustering, we
151 applied topic modeling to our scATAC-seq data. Topic modeling represents each cell as a grade
152 of membership (referred to as “loadings” hereafter) to inferred topics^{16,17}. Each topic captures an
153 axis of variation in the data which may represent cell-types, contexts, or biological processes.
154 This allows us to identify peaks with differential accessibility across topics, and to measure the
155 importance of a peak to each topic (referred to as “scores” hereafter)¹⁸. As such, peaks with the
156 highest scores in each topic often reveal their associated biological functions.

157
158 We applied a topic modeling approach, fastTopics¹⁹, to our scATAC count matrix, and built models
159 for six to 20 total topics (referred to as “k” hereafter, **Methods**). As expected, the number of topics
160 greatly influences the resolution at which cell states and biological processes are captured. In our
161 k=6 model, topics largely delineate common immune cell-types including B cells, CD4 T cells,
162 CD8 T cells/NK cells, and monocytes. In our k=10 model, both CD8 T cells and NK cells are
163 represented by k8, which captures the cytotoxic signatures shared between these two cell-types
164 (**Fig. 2a**). We chose the model with 20 topics for all downstream analyses, as it captures the
165 majority of common cell-types and recognizable cell states in our PBMC data (**Fig. 2a, Extended**
166 **Data Fig. 2**).

167
168 We observed that multiple topics were almost exclusively used by certain cell-types, including B
169 cells (k1, k11), monocytes (k10, k12), and DC (k4) (**Fig. 2b**). In contrast, T cell subsets often map
170 to more than one topic, highlighting the subtle differences across T cell subsets and cell states,
171 and the challenges in using clusters to represent T cell states. One topic, k2, was ubiquitously
172 present in all cell-types. Upon investigation, we found that k2 loadings are highly correlated with
173 the TSS enrichment score. The top 3,000 peaks with the highest scores in k2 are over-

174 represented in promoter regions (p -value $< 2e-16$, hypergeometric test; **Extended Data Fig. 3a,b**),
175 suggesting that k2 likely represents single-cell data quality rather than biological variation.

176
177 To functionally annotate the different topics, we derived gene-level scores in each topic from the
178 peak-level scores. We tested four different peak-to-gene mapping strategies and found that
179 distance-based exponential weighting function from ArchR performed the best on our
180 benchmarking (**Extended Data Fig. 3c, Methods**)²⁰. Using this strategy, we identified a set of
181 genes driving each topic and we observed well-known cell-type markers among the highest-
182 scoring genes, including *EBF1* and *CD83* for naive B cells (k1); *CD27* and *TNFSF9* for memory
183 B cells (k11); *CD247* and *ZBTB16* for NK cells (k8); *S1PR5*, *KLRD1*, *PRF1* and *TBX21* for
184 cytotoxic CD8 T cells (k3); and *ICOS* and *CTLA4* for Treg cells (k20) (**Fig. 2c, Supplementary**
185 **Table 2**). The high-scoring genes in each topic were also enriched in relevant biological process
186 gene sets (**Extended Data Fig. 3d; Supplementary Table 3**). Finally, we tested the enrichment
187 of transcription factor (TF) binding motifs in the top 3,000 peaks with the highest scores for each
188 topic (**Supplementary Table 4**). Again, TFs known for immune cell-types and states show
189 significant enrichment in the corresponding topics (**Extended Data Fig. 3e**).

190
191 Cell transitions from one state to another (e.g. during disease progression) generally exhibit a
192 continuous rather than a discrete change in gene expression^{21,22}. We reasoned that the loading
193 of topics corresponding to a cell state transition captures the cell trajectory along possible
194 transitions. Indeed, we identified evidence that topic k1 loadings represent the transition between
195 naive B cells to memory B cells (**Methods**). For example, we observed progressive enrichment
196 of non-naive B cells (including memory B cells and plasmablasts) along the k1 trajectory (**Fig. 2d**,
197 top). We also adapted the ArchR getTrajectory algorithm to identify genes with changing activities
198 along memory B cell trajectory and observed decreasing GA scores for naive B cell marker genes
199 (*IL4R*, *TCL1A*, *IGHM*, *IGHD*) and increasing GA scores for memory B cells marker genes (*AIM2*,
200 *CD27*, *COCH*) (**Fig. 2d**, bottom) (**Supplementary Table 5**). Thus, cell loadings from our topic
201 modeling effectively and directly capture biologically-meaningful trajectories along cell states.

202
203 Finally, we determined the relevance of each topic in terms of explaining complex disease
204 heritability. We used stratified LD score regression (s-LDSC)⁸ to calculate heritability enrichment
205 of each topic across 50 GWAS traits (**Supplementary Table 6**). As expected, we observed
206 greater h^2_g enrichment in many immune-related diseases and blood phenotypes compared to
207 height, a trait used as negative control. Notably, we found large h^2_g enrichment for three
208 autoimmune diseases (RA, systemic lupus erythematosus [SLE] and multiple sclerosis [MS]) in
209 the lymphoid-related topics (**Fig. 2e**). For SLE, B cell topics (k1 and k11) are the most enriched,
210 consistent with the known role of B cells in SLE etiology^{23,24}. In addition, monocyte and myeloid-
211 related GWAS (MONO%, MONO#, GRAN%MYELOID) are enriched in monocyte-related topics
212 (k5, k9, k10, k12, k13, k15; **Fig. 2e**), in line with the expectation that cellular programs in
213 monocytes causally regulate myeloid cell numbers and proportions. Interestingly, we found that
214 one topic, k17—which was found in some CD8 T and non-classical T cells—was significantly
215 enriched for heritability for both hospitalized and critical COVID-19 GWAS (**Fig. 2e**).

216 Thus, our analyses identify cell states and regulatory programs that likely mediate genetic
217 risks for several complex immune traits.

218

219 **Topic-derived cell trajectories identify COVID-19-associated cell state continuums**

220

221 We next sought to find topics that may be associated with COVID-19. As we found k17 to be
222 significantly enriched for COVID-19 GWAS heritability, we tested the association between k17
223 loadings and cell donor COVID-19 status to assess whether cell donor active COVID-19 status
224 explains a significant proportion of variation in loadings (**Methods**). Indeed, k17 is significantly
225 enriched for COVID-19 cells (p-value = 0.023). Topic k17 largely represents CD8 TEM, and cells
226 with high k17 loadings are disproportionately from COVID-19 donors (**Fig. 2f**, top), suggesting an
227 expanded CD8 TEM population in COVID-19 patients.

228

229 To further investigate k17, we built a trajectory using k17 loadings and grouped cells by trajectory
230 quintiles (**Fig. 2f**). We found that several genes previously linked to COVID-19 showed varying
231 chromatin accessibility along the k17 trajectory (**Supplementary Table 7**). For example, we
232 observed decreased accessibility around the *PRG4* gene body along the k17 trajectory²⁵, while
233 accessibility increased around *CCL3* and *CCR2*²⁶ (**Fig. 2g**). Taken together with the independent
234 observation that high-scoring k17 peaks are enriched in COVID-19 heritability (**Fig. 2d**), our
235 results suggest that an expanded CD8 TEM cell population in peripheral blood is a hallmark of
236 COVID-19 and that CD8 TEM cells—or related cells—are important mediators of COVID-19 genetic
237 risk.

238

239 More generally, we compared GA scores in COVID-19 cells across quintiles against healthy cells.
240 COVID-19 cells in higher quintiles exhibited more differentially active genes than those in lower
241 quintiles (**Extended Data Fig. 3f**, **Supplementary Table 8**). Notably, these differentially active
242 genes were enriched in pathways related to chemotaxis, immune cell migration and T cell
243 activation, consistent with the immune response upon COVID-19 infection (**Extended Data Fig.**
244 **3g**). These findings complement our observation that k17 is enriched with COVID-19 cells and
245 COVID-19 heritability and could not be replicated using a cluster-based approach. These results
246 demonstrate the utility of modeling continuous cell states using a topic modeling framework.

247

248 **A high-resolution map of caQTLs in PBMCs**

249

250 We next used our harmonized dataset to map the impact of genetic variation on chromatin
251 accessibility in multiple cell-types. To map caQTLs, we first used RASQUAL to model both intra-
252 individual allelic-imbalance and inter-individual variation in chromatin accessibility for SNPs in a
253 10 Kb window flanking the peak center in PBMCs (aggregating all cells from a donor) as well as
254 the seven immune cell-types defined in our L1 annotation. We used phenotypic principal
255 components (PCs), genotype PCs, and multiple quality control measurements²⁷ as covariates
256 (**Methods**, **Extended Data Fig. 4a**). In total, we identified 37,390 caQTLs (corresponding peaks
257 are referred as cPeaks hereafter, making up 11.7% of all tested peaks), 8,792 of which were
258 discovered in L1 cell-types (**Fig. 3a**), but not when aggregating all PBMC cells. This far surpasses
259 the number of significant caQTLs identified in previous studies^{9,28}.

260

261 To verify that the caQTLs we found are likely true positives, we separately mapped PBMC caQTLs
262 in each of the three scATAC-seq datasets. We found multiple lines of evidence indicating that the
263 caQTLs uniquely identified in our harmonized data (“novel caQTLs”) are *bona fide* caQTLs. First,
264 novel caQTLs showed allelic imbalance in the smaller dataset from Benaglio et al., despite being
265 non-significant (**Fig. 3b**). Second, both our total caQTL set and novel caQTLs are strongly
266 enriched in bulk caQTLs from lymphoblastoid cell lines (LCLs) (**Fig. 3c**)²⁹. Finally, caQTLs in L1
267 cell-types showed cell-type specific enrichment in eQTLs from 15 immune cell-types in the DICE
268 consortium^{1,30}. For instance, caQTLs in monocytes and B cells are the most enriched for eQTLs
269 in classical/non-classical monocytes and naive B cells in DICE, respectively (**Fig. 3d**). Similarly,
270 caQTLs in CD4 T cells were broadly enriched in eQTLs across various T cell subtypes in DICE.
271 When visualizing the p-value distribution of caQTL SNPs in DICE eQTLs, a similar trend emerged
272 (**Fig. 3e**). We also obtained single-cell eQTLs identified from scRNA-seq data collected from 63
273 COVID-19 and 106 control donors, of which 25 donors overlap ours (**Randolph et al.**). Again, we
274 found cell-type-specific enrichment of caQTLs in eQTLs in matched cell types (**Extended Data**
275 **Fig. 4b**). Together, this evidence suggests that our caQTLs are likely to be true positives.

276
277 The goal of our work is to determine the extent to which caQTLs can explain immune disease-
278 associated loci. However, RASQUAL does not report effect size and standard error of identified
279 caQTLs, which complicates statistical integration of RASQUAL caQTLs with GWAS summary
280 statistics. Additionally, caQTLs mapped using RASQUAL are biased toward heterozygous SNPs
281 with high read coverage, as SNPs outside peaks have weaker or no allele-specific signal, and
282 lower phasing accuracy. To adapt single-cell caQTL data for colocalization analysis³¹, TWAS^{32,33},
283 mashr³⁴ and meta-analysis³⁵, we used a single-cell Poisson mixed-effects model (sc-PME)³⁶ to
284 generate standard summary statistics of caQTL effects. In addition to providing critical statistics
285 for downstream statistical analyses, sc-PME allows a larger mapping window (250Kb) compared
286 to the 10Kb used in RASQUAL. This window is difficult to extend in RASQUAL because it requires
287 haplotype phasing, which worsens as a function of distance. Yet, a larger mapping window may
288 help capture additional significant caQTLs (**Extended Data Fig. 4c**).

289
290 To reduce computational time and avoid inflated p-values due to high dropout rates in scATAC
291 count data, we restricted our analysis to the 37,390 significant cPeaks from RASQUAL in PBMC
292 and L1 cell-types. As expected, we did not find many caQTLs in underrepresented cell-types
293 (5,006 caQTLs in DC and 3,662 caQTLs in “Other T Cells”, 10% FDR). However, in the other 5
294 immune cell-types, we identified 10,739-22,785 caQTLs (mean: 16,297; 10% FDR). We then
295 compared sc-PME results to those from RASQUAL, focusing specifically on the effect size
296 estimates at top caQTL SNPs. We observed high concordance between the two approaches (e.g.
297 98.08% in monocytes; **Fig. 3f**), supporting the validity of the sc-PME results. We also found that
298 across L1 cell-types, an average of 79.1% of RASQUAL caQTLs are replicated by sc-PME. As
299 anticipated, the rate of replication is lowest among rare cell-types (**Fig. 3g**). Finally, compared to
300 a single-cell linear mixed-effects model, effect sizes from sc-PME had higher reproducibility and
301 correlation with RASQUAL caQTLs (**Extended Data Fig. 4d**).

302
303 We hypothesized that sc-PME would allow us to map caQTLs missed by RASQUAL owing to
304 larger testing window sizes. To test this, we analyzed 1,337 peaks in B cells whose sc-PME lead

305 QTLs are more than 10 Kb away from the cPeak center but reside in distal chromatin accessibility
306 peaks, as these cases are more likely to capture distal causal effects. These distal peaks are
307 enriched in cPeaks (8.9% versus 3.4% genome-wide, $p < 2e-16$; hypergeometric test), suggesting
308 that sc-PME captures *bona fide* distal caQTLs that are missed by RASQUAL. We highlight a peak
309 (chr10:47599729-47600229) whose lead RASQUAL caQTL is located within the cPeak itself, but
310 the lead sc-PME caQTL is ~50 Kb upstream, is much more statistically significant, and colocalizes
311 with an eQTL for gene *ANTXR1P1* in B cells (PP4=0.95, **Fig. 3h**). Thus, beyond providing critical
312 summary statistics (i.e. Z-scores) that can be used for downstream statistical analyses, sc-PME
313 can also help capture causal SNPs that are invisible to RASQUAL.

314

315 In addition to identifying caQTLs in the L1 cell-types, we identified dynamic genetic effects along
316 cell trajectories as defined by loadings from our topic modeling. Specifically, we tested for the
317 linear interaction between lead caQTL in the L1 cell-types and the loadings of each topic
318 (**Methods**), which capture a continuum of cell states along different axes of biological variation.
319 We only mapped dynamic caQTLs in each cell type to avoid confounding with cell-type specific
320 caQTLs. In total, we identified 4,200 peaks (Q-value < 0.01) that have at least one dynamic caQTL
321 in one or more cell-type-topic pairs. On average, we detected 158 significant dynamic caQTL in
322 each cell-type-topic pair and, as expected, we found that the number of cells in a topic greatly
323 influenced the statistical power for calling dynamic caQTLs (**Fig. 3i**).

324

325 To showcase examples of dynamic caQTLs, we highlight k17-interacting caQTLs in CD8 T cells.
326 We divided dynamic caQTLs into two groups: (i) Consistently significant, which are significant
327 along the entire k17 trajectory, but with varying effect sizes, and (ii) Partially significant caQTLs,
328 which have significant effects in parts of the trajectory. The variability in the effect sizes of these
329 caQTLs along the k17 trajectory is visualized and contrasted with that of randomly chosen non-
330 dynamic caQTLs (likelihood-ratio test p-value > 0.5) (**Fig. 3j**). To map dynamic caQTL peaks to
331 genes, we used the Activity-by-Contact (ABC) model and found that genes associated with k17
332 dynamic caQTLs were enriched in immune and disease-related pathways, including natural killer
333 cell mediated cytotoxicity (GO:0002228, p-value=2.61e-8) and regulation of lymphocyte activation
334 (GO:0051249, p-value=3.36e-7) (**Extended Data Fig. 4e**). Additionally, several linked genes in
335 ABC model were also implicated in the k17-associated COVID-19 genes we identified in topic
336 analysis, including *IFNLR1*, *IL5RA*, *IL6ST*, *KLRC4*, *KLRD1*, *KLRK1*, *SYNGR1*, *TLR1* and
337 *TNFSF14*.

338

339 In summary, we established a map of 37,390 static and 4,200 dynamic caQTLs in PBMC and
340 common immune cell-types. Not only do these caQTLs capture the impact of genetic variants on
341 chromatin accessibility in common immune cell-types, but they also capture dynamic effects that
342 manifest in important cell contexts such as cytotoxic cells. Summary statistics for all caQTLs can
343 be readily used in standard and popular downstream analyses and are publicly available (Zenodo:
344 TBD).

345

346 **Sharing and specificity of caQTLs and eQTLs across cell-types and states**

347

348 Observations from single cell RNA-seq studies suggest that eQTLs and caQTLs are largely cell-
349 type-specific^{9,28,37}. In contrast, molQTL maps derived from bulk RNA-seq data suggest that most
350 QTL effects are shared across cell-types^{1,38-40}. We sought to systematically evaluate the
351 specificity of caQTL effects across the seven immune cell-types in our L1 annotation, and to
352 evaluate their cell-type specific impact on gene expression levels.

353
354 We first compared the sharing of our sc-PME caQTLs. The general picture that emerged is that
355 the majority of caQTLs are shared among all seven immune cell-types, except for monocytes, for
356 which 42.5% of caQTLs identified were monocyte-specific. Still, only an average of 18.8% of
357 caQTLs were cell-type specific, and this number is even lower after excluding monocytes (12.9%,
358 **Fig. 4a**). Interestingly, these results suggest much higher QTL sharing than those obtained from
359 RASQUAL caQTLs, for which 20,851 (68.5%) were unique to one cell-type, and merely 49
360 caQTLs were shared in all seven cell-types (**Fig. 4b**). Thus, the discrepancies in sharing between
361 RASQUAL and sc-PME are explained by statistical power, and further increasing QTL mapping
362 power will yield higher estimates of sharing. We conclude that the prevalence of cell-type specific
363 QTLs observed in single-cell genomics compared to bulk genomics data is likely explained by low
364 QTL mapping power rather than cell-type specificity. For this reason, we used sc-PME caQTL
365 results for all analysis below.

366
367 Chromatin accessibility QTLs are expected to regulate promoter or enhancer activity with an effect
368 on the expression level of one or multiple nearby genes; therefore, we asked whether our sc-PME
369 caQTLs are also eQTLs in the DICE dataset or in the scRNA-seq dataset from matched COVID-
370 19 patients and controls. As the DICE dataset consist of 15 bulk sorted immune cell types from
371 ~90 individuals³⁰, we matched the 15 cell-types/states available to five cell-types in our scATAC
372 data (excluding DC and “Other T cells” in L1 annotation; **Extended Data Fig. 5a**). In total, we
373 identified 6,228 unique caQTL-eQTL pairs that colocalized in at least one DICE-matching context
374 (referred to as COLOC caQTL-eQTL pairs hereafter), including 2,635 eGenes (24% of all tested)
375 (**Supplementary Table 9**). In comparison, when using our eQTLs from scRNA-seq of matched
376 COVID-19 patients and controls (Randolph et al.), we found fewer caQTL-eQTL colocalizations
377 (representing only 203 cPeaks, or 2.6% of all tested; **Fig. 4c**). This is possibly due to the sparsity
378 of the PBMC scRNA-seq data compared to bulk RNA-seq of sorted immune cells. We therefore
379 used caQTL colocalizations with DICE eQTLs for downstream analyses.

380
381 We made two notable observations from this analysis. First, a very small fraction of caQTLs
382 colocalizes with an eQTL. Across five contexts, only 4,088 cPeaks (18.6% of all tested) were
383 colocalized with an eQTL (i.e. “eQTL-caQTL”). This suggests that the majority of caQTLs do not
384 influence the expression level of a nearby gene in the many immune cell-types and contexts
385 included in the DICE dataset (**Fig. 4c**). Second, even when an eQTL colocalizes with a caQTL in
386 DICE, it often does so in just a single context. Indeed, 5,995 (84.5%) of all caQTL-eQTL pairs
387 exist in just one context. This is in stark contrast to the widespread sharing of caQTL we observed.
388 In fact, the majority of caQTLs shared between cell-types do not have shared colocalization with
389 an eQTL. For example, among the 3,091 caQTLs with effects in both CD8 T cells and monocytes,
390 only 134 were eQTL-caQTLs in both cell-types. This number is notably small considering that
391 4,805 and 7,425 eQTL-caQTL colocalizations were identified in CD8 T cells and monocytes,

392 respectively (**Fig. 4c**). For example, cPeak chr11:60018902-60019402 has a shared caQTL in
393 monocytes and CD8 T cells, but only colocalized with an *MS4A4A* eQTL in monocytes (**Fig. 4d**).
394 Similarly, shared cPeak chr1:89742288-89742788 only colocalized with *GBP5* in naive CD8 T
395 cells in DICE (**Fig. 4d**). In both cases, the lack of colocalization is attributed to the absence of
396 eQTL signals. Thus, we find that eQTL effects are more cell-type specific compared to caQTLs
397 at a large number of loci.

398
399 To understand how caQTLs impact gene expression levels in a cell-type specific manner despite
400 affecting accessibility in multiple cell-types, we sought to identify genomic factors that can predict
401 the presence or absence of caQTL-eQTL colocalizations. To this end, we used a logistic
402 regression model to predict caQTL-eQTL colocalization with (1) gene expression level, (2)
403 chromatin accessibility level, (3) enhancer-to-gene links from ABC model⁴¹ in matched cell-types
404 and (4) whether a caQTL-eQTL pair colocalize in multiple cell-types. Notably, gene expression or
405 chromatin accessibility levels were not predictive of caQTL-eQTL colocalization, suggesting that
406 statistical power does not explain the lack of caQTL effects on gene expression levels.
407 Interestingly, although many caQTL-eQTL colocalizations are cell-type specific, we found that a
408 strong predictor for caQTL-eQTL colocalization in a given cell-type is the presence of a caQTL-
409 eQTL colocalization in another cell-type (**Fig. 4e**), consistent with the notion that *cis*-regulatory
410 elements – particularly promoters – control the same genes across cell-types. We found that the
411 second most predictive feature was enhancer-to-gene links from the ABC model (most predictive
412 in monocyte: log₂ effect=1.007, p-value=1.63e-66; least predictive in CD8 T cell: log₂ effect=0.44,
413 p-value=4.70e-7), providing a mechanistic explanation for cell-type specific caQTL effects on
414 gene expression levels. These findings highlight the importance of distinguishing “merely active”
415 accessibility peaks from “functional” peaks in caQTL analyses. Critically, our observations indicate
416 that a large fraction of caQTLs have no impact on gene expression levels in any given cell-type
417 because they are not physically connected to any gene in that cell-type.

418
419 We also asked whether the presence of specific TF binding motifs could predict eQTL-caQTL
420 colocalization in a cell-type. We focused on a comparison between CD8 T cells and monocytes
421 as many TFs driving accessibility of these two cell-types differ and have been well characterized.
422 Interestingly, we found that, compared to all peaks as background, cPeaks with cell-type specific
423 caQTL-eQTL colocalizations were enriched for known lineage-associated TF motifs, e.g. RUNX1,
424 RUNX2 and CFBF in CD8 T cells, and CEBPA, CEBPB and SPIB in monocytes. By contrast, we
425 found that shared caQTL-eQTL colocalizations are enriched for TFs with broad activity, including
426 ELK4 and E2F1 (**Fig. 4f**). These results suggest that cell-type-specific TFs can potentiate the
427 impact of caQTLs on gene expression in a cell-type-specific manner.

428
429 To find potential cellular contexts in which CD8 T cell or monocyte cPeaks without eQTL
430 colocalization might potentiate an eQTL effect, we asked whether cPeaks without any eQTL
431 colocalization were enriched in any recognizable TF binding motifs. In CD8 T cells, we found
432 similar enrichments for a subset of TFs (including RUNX1, RUNX2, CFBF) in cPeaks with or
433 without eQTL colocalizations. However, motifs for another set of TFs (including EOMES, RUNX3
434 and TBX20) were significantly enriched in cPeaks without eQTL colocalization (**Fig. 4g**, left).
435 Notably, EOMES, RUNX3 and TBX20 are all highly enriched in accessible regions of CD8 TEM

436 cells (**Fig. 4g**, right), supporting a potential gene regulatory function of these caQTLs in CD8 TEM
437 cells. Further supporting this possibility, EOMES regulates differentiation of effector and memory
438 CD8 T cells, and is also implicated in exhaustion; and RUNX factors are associated with CD8 T
439 effector/memory (TEM) populations⁴²⁻⁴⁴. Although DICE dataset contains eQTLs from 15 different
440 immune cell-types including activated CD8 T cells, it lacks eQTLs from exhausted or long-term
441 memory CD8 T cells. Thus, many cPeaks lacking eQTL colocalizations likely correspond to
442 poised or “primed” enhancers⁴⁵ that can impact gene expression levels in a cell-type-specific
443 manner through activation of cell-type-specific TFs.

444
445 Taken together, our findings suggest that the impact of genetic variants on chromatin accessibility
446 can be detected in many cell-types. However, whether chromatin accessibility at these regions
447 influences gene expression levels depends on cell-type specific TFs, resulting in cell-type specific
448 eQTL effects that are difficult to predict from caQTLs alone.

449

450 **GWAS loci colocalize more often with caQTL than eQTLs**

451
452 We sought to characterize the utility of our caQTLs for interpreting immune-related GWAS loci.
453 We colocalized sc-PME caQTLs with GWAS of 11 immune-related diseases, two COVID-19
454 phenotypes and 36 blood phenotypes. We compared these results with eQTL-GWAS
455 colocalization from DICE⁴³. In total, 56.8% (4,696 out of 8,271) of GWAS loci across all traits
456 (GWAS-SNP pairs) colocalized either a caQTL or an eQTL (n=1,532), only caQTLs (n=2,015), or
457 only eQTLs (n=1,149) (**Supplementary Table 10,11**).

458
459 Among GWAS loci that colocalizes with both, we found an RA locus⁴⁶ that colocalizes with a
460 *PVRIG* eQTL in Tfh and Tregs, and a caQTL in CD4 T cells. *PVRIG* (also known as *CD112R*) is
461 a co-inhibitory receptor for T cells⁴⁷. The convergence of evidence from gene expression and
462 chromatin accessibility suggests that genetically determined *PVRIG* expression changes underlie
463 RA risks, potentially by modulating T cell activation (**Extended Data Fig. 5b**). As an example of
464 GWAS locus that colocalizes with only eQTLs, *RPS26* gene has a strong eQTL that is shared in
465 all immune cell-types in DICE colocalizing with an RA locus (12:56470625; PP4: 0.93-0.95).
466 Interestingly, the TSS peak of *RPS26* (chr12:56435365-56435865) is accessible in all cell types,
467 but their caQTL did not colocalize with the RA GWAS locus, suggesting possible alternative eQTL
468 mechanisms⁴⁸ (**Extended Data Fig. 5c**).

469
470 GWAS loci that colocalize with caQTL but not eQTLs (caQTL-only) are more difficult to interpret.
471 Yet, this category was the largest colocalization category of all, and greatly increased the number
472 of explained GWAS loci from an average of 32.9%, when considering eQTLs alone, to 57.3%
473 when adding caQTLs (**Fig. 5a**). These findings mirror results from recent studies^{5,6,49}, which also
474 found that many GWAS loci are associated with changes in chromatin-level phenotypes but not
475 mRNA levels. This led us to wonder how GWAS loci that colocalizes with a caQTL but not an
476 eQTL might function.

477
478 To nominate causal genes at caQTL-only GWAS loci, we focused on cPeaks overlapping with
479 TSS. In total, 220 (15.3%) GWAS-caQTL loci mapped to promoter regions, which allowed us to

480 nominate a putative causal gene. For example, we identified a peak ~100 bp upstream of the
481 gene *ZFP36L1*. In CD4 T cells, the same caQTL colocalized with multiple GWAS including CD,
482 ulcerative colitis (UC), RA and MS, suggesting it may affect a common mechanism underlying
483 multiple autoimmune diseases. *ZFP36L1* is an RNA-binding protein that is differentially expressed
484 in osteoarthritis and coeliac disease and has been shown to regulate T cell and B cell
485 development⁵⁰⁻⁵², although its exact mechanism in other autoimmune diseases remains unknown
486 (**Supplementary Fig. 5d**). In another case, the promoter peak (chr22:37256806-37257306) for
487 gene *NCF4* has a caQTL colocalizing with an RA GWAS locus in NK and CD8 T cells
488 (**Supplementary Fig. 5e**). *NCF4* has been identified as a risk gene for RA by genetic associations
489 previously; it might be linked to NADPH metabolism in RA and can also regulate NK/CD8 T cell
490 frequencies⁵³⁻⁵⁵. However, previous eQTL studies did not nominate this gene for RA. These cases
491 suggest that caQTL-GWAS colocalization can, in a limited number of cases, find putative disease
492 genes. The 220 caQTL-only colocalizations gene promoters can be found in **Supplementary**
493 **Table 12**.

494
495 We also asked whether cell-type specific caQTLs or dynamic caQTLs across our defined topic
496 trajectories could explain GWAS hits. On the one hand, we found that cell-type specific caQTLs
497 are less likely to colocalize with GWAS hits compared to shared caQTLs or all caQTLs combined.
498 On the other hand, dynamic caQTLs were more likely to colocalize with GWAS hits than other
499 types of caQTLs, suggesting that caQTLs with dynamic effects tend to capture trait-relevant
500 regulatory elements (**Fig. 5b**). Using the RA GWAS as an example, we found that 24 out of 69
501 (34.8%) GWAS loci that colocalized with a caQTL have an underlying dynamic effect on chromatin
502 accessibility, significantly more than expected by chance (OR=2.27, p-value=1.70e-05; Fisher's
503 exact test). These results suggest that identifying caQTLs with dynamic effects may help interpret
504 GWAS hits. Still, dynamic caQTLs contributed to very few colocalization with GWAS in absolute
505 numbers because the vast majority of caQTLs do not exhibit dynamic effects, at least at current
506 sample sizes (**Fig. 5c**).

507 508 **Limited convergence of caQTL and eQTL signals prevents functional interpretation of** 509 **most trait-associated loci**

510
511 We have shown that most GWAS-caQTL colocalizations do not have a corresponding
512 colocalization with an eQTL, and that only a small number of these colocalizations are likely to
513 help with causal gene identification because they impact a gene promoter. We next turned to the
514 GWAS loci that colocalized with both an eQTL and a caQTL and show improved identification of
515 causal disease genes only when both caQTL and eQTL colocalize in the same cellular context.

516
517 We first examined the cell-type contexts that were implicated by GWAS loci with both a caQTL
518 and an eQTL colocalization (caQTL+eQTL loci). To allow comparisons between our eQTL and
519 caQTL contexts, we assigned the 15 DICE cell-types to one of the five common immune cell-type
520 contexts defined in our scATAC-seq data (**Extended Data Fig. 5a**). We found that a substantial
521 fraction (375/1,532, 25.4%) of the caQTL+eQTL loci colocalized with the caQTL and eQTL in
522 distinct cell-types (**Fig. 5d**). We also observed that GWAS loci that colocalize with a caQTL or
523 eQTL in multiple contexts tend to colocalize with multiple distinct peaks and eGenes, respectively

524 **(Extended Data Fig. 6a,b)**. These observations suggest pleiotropic genetic effects for a
525 substantial fraction of GWAS loci, which hinders our ability to identify which gene or cell context
526 is likely causal for the trait of interest.

527
528 We found that 24.4% of caQTL-GWAS colocalizations also colocalize with an eQTL in the same
529 contexts. We hypothesized that eQTLs at these GWAS loci more likely pinpoint the causal
530 disease gene as both caQTL and eQTL converge in the same context. To test this, we leveraged
531 the SNP-to-gene pairs database (S2G)⁵⁶ as a ground truth for causal SNP-to-gene effects. We
532 tested the enrichment of SNP-to-gene links inferred from our QTL data among S2G pairs, using
533 the closest gene as baseline (**Fig. 5e**). We found that caQTL+eQTL S2G pairs in overlapping
534 contexts are significantly enriched for S2G links ($\log_2\text{OR} = 0.70$, $p\text{-value} = 7.64\text{e-}8$; Fisher's exact
535 test), whereas caQTL+eQTL pairs in different contexts were depleted with S2G links ($\log_2\text{OR}=-$
536 0.35 , $p\text{-value}=7.95\text{e-}3$) (**Fig. 5f**). Furthermore, we found no enrichment in S2G pairs when using
537 the eGene to link SNPs to genes at GWAS loci colocalized only with an eQTL ($\log_2\text{OR}=-0.31$, $p\text{-}$
538 $\text{value}=1.89\text{e-}2$), or when using the nearest TSS to the cPeak at caQTL-only GWAS loci ($\log_2\text{OR}=-$
539 0.02 , $p\text{-value}=0.89$) (**Fig. 5f**). Thus, GWAS colocalization with a caQTL and an eQTL in the same
540 cell context is helpful for determining causal genes. Conversely and notably, colocalization with a
541 caQTL or eQTL alone or in non-overlapping contexts does not help identify causal genes, at least
542 compared to simply using the nearest gene.

543
544 Using GWAS loci that colocalized with a caQTL and eQTL in the same contexts, we were able to
545 narrow down the possible causal genes to no more than two genes and two contexts for hundreds
546 of loci. Many of the candidate genes and cellular contexts have known roles in disease etiology.
547 For instance, one inflammatory bowel disease (IBD) GWAS locus 9:139269198 colocalized with
548 eQTLs of *CARD9* and *SDCCAG3* in monocytes, and that of *DNLZ* in TH1-17 cells. The same IBD
549 locus is also colocalized with two caQTLs in monocytes and NK cells. Thus, we nominated
550 *CARD9* and monocytes as the likely causal gene and context for this GWAS locus. In support of
551 this, *CARD9* (but not *SDCAG3*) is one of the well-established causal genes in IBD⁵⁷⁻⁵⁹, and it is
552 the only gene linked to the GWAS SNP 9:139269198 in the S2G database (S2G score=1, the
553 largest possible score in S2G). Furthermore, the colocalized peak is predicted to be connected to
554 *CARD9* TSS in monocytes in the ABC model, whereas no enhancer-TSS links were found in T
555 cells. *CARD9* is highly expressed in classical and non-classical monocytes, whereas *DNLZ* is
556 lowly expressed in TH1-17 cells. The identified peak (chr9:139271584-139272084, ~13.3Kb
557 upstream of *CARD9* TSS) is also monocyte-specific and harbors fine-mapped IBD GWAS SNPs
558 (**Fig. 5g**). This example highlights the need to consider multiple lines of molecular information to
559 obtain a set of high-confidence targets, and supports our interpretation that caQTL or eQTL
560 colocalization can be misleading.

561
562 In conclusion, GWAS colocalization with both a caQTL and an eQTL gives us the best chance at
563 identifying the causal genes and contexts underlying trait association. However, most caQTL-
564 GWAS colocalization identified in our study did not colocalize with an eQTL in any context. Thus,
565 although genetic effects on chromatin accessibility across multiple immune cell-types and
566 contexts drastically increase GWAS loci colocalization rates to a molecular QTL, our work suggest

567 that they should be interpreted with caution as their effects on gene expression levels are yet
568 unidentified.

569

570 **Discussion**

571

572 In this study, we constructed a harmonized map of single-cell chromatin accessibility
573 accompanied with high-quality genotype information. Unlike single cell eQTLs studies which have
574 become streamlined with the development of new approaches and best practice^{60,61}, there exists
575 few studies and approaches for caQTLs mapping in single cells. We show that by applying both
576 allelic-imbalance modeling in RASQUAL and the sc-PME model, we can identify a set of high-
577 confidence caQTLs whose summary statistics can be used for state-of-the-art downstream
578 analyses. In total, we were able to identify 37,390 caQTLs from our integrated scATAC-seq
579 dataset, which quadrupled the number of caQTLs from that reported in a recent, smaller study³⁶.
580 We also utilized the continuous nature of cell loadings in topic analysis to map dynamic caQTLs.
581 We find that topics are more straightforward to interpret compared to principal components³⁶.

582

583 Remarkably, we found that adding caQTLs increases colocalized GWAS loci by an average of
584 ~50% compared to eQTLs alone, suggesting that mapping caQTLs in single cells may be a
585 promising paradigm for studying and biologically interpreting disease associated variants. As such,
586 our work corroborates similar findings reported from recent bulk caQTL studies⁴².

587

588 Still, there has been no straightforward explanation as to why, in any given cell-type context, many
589 GWAS loci only have effects on chromatin, but not on gene expression level. We found that the
590 sharing of caQTLs across immune cell-types is widespread, but their impact on gene expression
591 levels is much more restricted owing to cell-type specific gene expression and/or cell-type specific
592 enhancer-promoter interaction. Thus, we interpret novel caQTL-GWAS colocalization results with
593 caution. We posit that many – if not most – caQTL-GWAS colocalizations do not reflect meaningful
594 regulatory effects in a causal cell-type context. Thus, finding the gene and cell-type context that
595 causally mediates genetic effects on complex traits may be difficult even when a caQTL-GWAS
596 colocalization has been found. Our findings that caQTLs are widely shared across immune cell-
597 types and states indicate that most of these caQTLs may impact gene expression levels in
598 immune contexts for which eQTLs are unavailable. Thus, increasing the cell context coverage
599 maps of eQTLs will help in finding more cell-type contexts in which caQTL, eQTL, and GWAS
600 signals all align, but this will also lead to uncertainty in which context is most relevant for the trait.

601

602 Our findings are consistent with the existence of poised or primed enhancers, which are
603 accessible in many cell-types and states, but affect expression level of nearby genes only when
604 context specific transcription factors are activated (e.g. upon immune stimuli or during
605 differentiation)⁴⁵. However, the concept of primed enhancer does not generalize well across very
606 different immune cell-types such as B cells and monocytes, in which many open chromatin
607 regions are shared, but their impact on gene regulation may differ. Of note, a recent multi-modal
608 study shows that open chromatin states are shared among various RA-associated cell-states,
609 whereas the gene expression profiles are distinct⁶². More work is required to figure out how the
610 same *cis*-regulatory region can impact different genes in different cell-types. But what is clear is

611 that these effects appear prevalent and complicates fine-mapping of causal genes at disease
612 GWAS loci.

613
614 In conclusion, we demonstrate the utility of chromatin accessibility data in the functional study of
615 regulatory elements, but we argue that caQTL data — especially those without clear effects on
616 gene expression levels — often do not have any downstream regulatory impact. Thus, we
617 highlight the need for integrating additional and orthogonal information such as eQTL data,
618 enhancer-promoter links (e.g. ABC score), and other functional data to elucidate mechanisms of
619 GWAS loci. Our findings suggest that population-scale studies using multi-omic single cell assays
620 in disease-relevant contexts will be instrumental in improving our ability to uncover the molecular
621 mechanisms through which individual non-coding variants impact disease risk. More
622 challengingly, our results suggest that we have yet to identify many of the causal cell-types for
623 GWAS traits. Mapping eQTLs in relevant cell populations from disease patients^{1,63,64} or from
624 organoids^{65,66} subject to diverse treatments may be a fruitful approach in this direction.

625 **Methods**

626 **Clinical sample collection.**

627 We collected PBMCs from 20 COVID-19 patients hospitalized in Montréal, Canada with COVID-
628 19 between April 2020 and December 2021 who initially presented with symptomatic, primary
629 infection. All acute phase samples were collected from unvaccinated patients within 20 days of
630 symptom onset. None received plasma transfer therapy. We also prospectively sample a subset
631 of the same patients during convalescent phase COVID-19 (n = 11), and healthy controls (n = 5).
632 The respective institutional IRBs approved multicentric protocol: MP-02-2020-8929. Written,
633 informed consent was obtained from all participants or, when incapacitated, their legal guardian
634 before enrollment and sample collection.

635
636 **scATAC-seq sample processing.**
637 **Initial preparation.** Cryopreserved samples were thawed and cultured in RPMI 1640 without
638 glutamine (Fisher) supplemented with 10% fetal bovine serum (Corning), 1% L-glutamine (Fisher),
639 and 0.01% gentamicin from 10 mg/mL stock (Fisher) overnight. After incubation, samples were
640 washed with PBS, passed through a 40µm filter, and manually counted with trypan blue staining
641 by brightfield hemocytometer.

642
643 **Nuclei isolation.** As in the demonstrated protocol CG000169, Rev. E, from 10X genomics, we
644 lysed each batch of 1 million cells with a IGEPAL 630 / digitonin based lysis buffer for 3 minutes
645 on ice. Nuclei were then washed once and resuspended in 7.5uL of 10X Genomics Nuclei Buffer.
646 Finally, 2.5uL of nuclei were counted by trypan blue staining on a hemocytometer.

647
648 **Single-cell ATAC library preparation and sequencing.**

649 **Single-cell ATAC capture.** We followed the 10X Genomics Chromium Next GEM Single Cell
650 ATAC Reagent kit with version #1.1. Nuclei were transposed by isothermal incubation at 37°C
651 and Post Gel Bead-in-Emulsion (GEMs) were generated by the 10X Controller and subjected to
652 PCR as described in the 10X User Guide, and post-incubation products were stored at -20°C until

653 downstream processing. Each sample was captured individually (i.e. without pooling) aiming for
654 5,000 nuclei from each sample to be captured.

655
656 **Single-cell ATAC library preparation.** Post GEM incubation cleanup and sequencing library
657 preparation were performed as described in the Single Cell ATAC Reagent Kits v1.1 User Guide
658 (10X Genomics). Briefly, we cleaned up post-incubation GEMs first with DynaBeads MyOne
659 SILANE beads (ThermoFisher Scientific) and then with SPRIselect reagent (Beckman Coulter).
660 Libraries were constructed by performing sample index PCR (98 °C for 45 s, 9 or 10 cycles of
661 98°C for 20 s, 67°C for 30 s, 72°C for 20 s, and 72°C 1 min) followed by SPRIselect size selection.

662
663 **Next-generation sequencing.** Prior to sequencing, all multiplexed single-cell libraries were
664 quantified using the KAPA Library Quantification Kit for Illumina Platforms (Roche) and pooled in
665 an equimolar ratio. Libraries were sequenced by 100 base pairs (read1: 50, i7: 8, i5: 16, read2:
666 50) on an Illumina NovaSeq 6000.

667
668 **Preprocessing of in-house and public scATAC-seq data.**

669 We processed data in all three studies from FASTQ files using the following pipeline. Reads were
670 processed using cellranger-atac v2.1.0 with an in-house GRCh37 reference genome generated
671 using scripts from 10X Genomic documentations (<https://support.10xgenomics.com/single-cell-atac/software/release-notes/references#GRCh38-2020-A-2.0.0>). We removed reads that were
672 unmapped, did not have primary alignment, failed platform/vendor quality checks, and had
673 duplicated or supplementary alignment; we only kept reads that were paired and mapped in
674 proper pairs ('samtools view -f 3 -F 3844'). We then removed allelic-biased reads using the
675 WASP⁶⁷ workflow implemented in Hornet. We converted the resulting BAM file from each library
676 into a fragment file using sinto v0.7.5 and loaded into an ArchR project separately. We then
677 analyzed each library separately to identify high-quality barcodes and remove doublets. As a first
678 pass, we excluded cell barcodes with fewer than 1,000 and more than 50,000 unique fragments,
679 with a TSS enrichment score lower than six for all libraries and excluded those with high ratios of
680 reads mapping to nucleosomes, mitochondrial genome or ENCODE blacklist regions in a library-
681 specific manner (**Extended Data Fig. 1b**). We also used AMULET⁶⁸ on BAM files to flag and
682 remove potential doublets (AMULET q-value < 0.1).

683
684
685 **Preprocessing and cell-type annotation of public scRNA-seq data.**

686 We re-analyzed previously published PBMC scRNA-seq data from COVID-19 patients⁶⁷. Count
687 matrix was downloaded from Human Cell Atlas webpage and converted to a Seurat object. As a
688 first pass, we ran Azimuth with PBMC reference to annotate all the cells. We compared Azimuth
689 L1 annotation (B, CD4 T, CD8 T, dendritic cells (DC), monocytes, natural killer cells (NK), other
690 T cells) with original cell type labels provided by the author, and only kept cells with consistent
691 labels.

692
693 **Basic analysis of scATAC-seq data**

694 Through the processing steps above, we identified a list of barcodes that represent high-quality
695 single cells with individual ID for each library. We then loaded the fragment files containing these
696 barcodes from all libraries to one ArchR project for integrated analysis. Dimension reduction on

697 this full dataset was performed on the binary tile matrix, selecting the top 30,000 variable tiles and
698 outputting 50 reduced dimensions with 'addIterativeLSI' function in ArchR. We then feed this LSI
699 projection to the 'reducedMNN' function in R package 'batchelor' to remove batch effects across
700 libraries⁶⁹. We implemented a wrapper function to add MNN-adjusted dimensions to the ArchR
701 project object, enabling downstream analysis within ArchR framework. Cell clusters were
702 identified with a resolution of 0.8. For visualization, the reducedMNN-adjusted LSI was used to
703 derive a UMAP embedding with 'minDist=0.8' and 'spread=1'.

704
705 To calculate gene activity scores (GA scores) from scATAC-seq profiles, we generated an in-
706 house gene reference set from the GENCODE v19 annotation. Basically, we started from all the
707 gene symbols in the full GENCODE annotation and removed those whose 'gene_type' map to
708 one of the following: snRNA, misc_RNA, snoRNA, rRNA, miRNA, pseudogene,
709 polymorphic_pseudogene, IG_V_pseudogene, TR_V_pseudogene, IG_C_pseudogene,
710 TR_J_pseudogene, IG_J_pseudogene, processed_transcript, sense_intronic,
711 3prime_overlapping_ncrna and sense_overlapping, keeping 32,885 genes on chr1-22 and chrX.
712 We then extracted the transcript start sites (TSS) and exons for these genes and constructed a
713 gene annotation object that was added into our ArchR project. Our custom annotation includes
714 important marker genes that are missed in the default hg19 annotation used by ArchR, such as
715 gene *LINC02446* (also known as *RP11-291B21.2*, **Fig. 1f**), a long non-coding RNA that marks
716 activated CD8 T cells⁹. Using this custom gene annotation, we then calculated the GA score using
717 'addGeneScoreMatrix' with default parameters in ArchR.

718
719 To better annotate cell-types in our scATAC-seq data, we integrated it with our Azimuth-annotated
720 scRNA-seq data and transferred the annotation labels to scATAC-seq cells. We first performed
721 unconstrained integration using the 'addGeneIntegrationMatrix' function in ArchR. We then
722 examined the confusion matrix between cell clusters and annotated cell-types. Several clusters
723 contained mixed cell-types from the reference dataset. Upon further speculation, we found these
724 clusters tend to have higher rates of mitochondrial DNA and lie between well-defined cell-types
725 in the UMAP, suggesting these cells are of lower quality or are potential unremoved doublets. We
726 excluded these cells from the dataset and performed constrained integration by restricting cells
727 within four groups: T/NK cells, monocytes/DC, B cells and other (platelet and HSPC). After this
728 round of constrained integration, we found several T/NK cell subtypes in L2 have very low cell
729 numbers in scATAC-seq data, we therefore only kept labels with sufficient cell numbers (CD14
730 Mono, CD16 Mono, NK, NK_CD56bright, NK Proliferating, pDC, cDC2, Platelet, B naïve, B
731 intermediate, B memory, Plasmablast, gdT, MAIT, CD4 Naïve, CD4 TCM, Treg, CD8 Naïve, CD8
732 TEM, CD8 TCM, HSPC) and performed another iteration of constrained integration. Finally, we
733 re-calculated the LSI, MNN-adjusted dimensions and the UMAP embedding and Leiden
734 clustering on the remaining cells.

735
736 To identify candidate peaks, we first produced pseudo-bulk group coverages in each Leiden
737 cluster and used the three studies as sample labels in
738 'addGroupCoverages(sampleLabels="Sample")'. We then called reproducible peak set by setting
739 'reproducibility=2' in 'addReproduciblePeakSet'. In this way, we were able to identify peaks that
740 are called in at least two of the three studies in our data.

741
742 **Genotype imputation from aggregated scATAC-seq data.**
743 Read coverage across the genome was visualized using 'plotCoverage' from deepTools⁷⁰,
744 excluding blacklist regions from ENCODE. Genotype likelihood calculation and imputation were
745 performed following GLIMPSE documentation⁶⁹. Briefly, we first inferred genotype likelihoods
746 across all SNPs in the 1000 Genome Project from filtered BAM files from scATAC data with
747 'bcftools mpileup'. In this step, we only included sites with sequencing depth below 15 ("bcftools
748 view -i 'FORMAT/DP<=15'") to avoid regions with unreasonably high read coverage. Next, we
749 merged genotype likelihood from all individuals from the three studies and performed GLIMPSE
750 genotype imputation jointly. Imputed genotypes were phased with eagle v2.4.1⁷¹.

751
752 To confirm GLIMPSE-imputed genotypes from scATAC-seq reads are of high quality and are not
753 biased by strong allele-specific signals in accessible chromatin regions, we compared Minimac4
754 imputation from microarray with GLIMPSE results in the 13 individuals with microarray data from
755 Benaglio et al⁷. We first imputed the microarray genotype data from the original study using the
756 pipeline documented in Michigan Imputation Server⁷²
757 (<https://imputationserver.readthedocs.io/en/latest/pipeline>). We used the same reference panel
758 as in our GLIMPSE pipeline. We then calculated mean imputation quality score (INFO score) for
759 SNPs stratified by reference MAF bins. We also calculated correlation between genotype dosages
760 for SNPs imputed using GLIMPSE and Minimac4 and derived mean correlation across the 13
761 individuals in each reference MAF bin using 'vcf-stats'.

762
763 **Topic modeling on scATAC count data.**
764 **Fitting the topic model.** Topic modeling was performed using the R package 'fastTopics'⁷¹. We
765 retrieved the cell-by-peak count matrix from the ArchR object. In practice, we considered two
766 aspects in fitting Poisson NMF to our count data. First, fitting the topic model on the full data is
767 computationally expensive. Second, the NMF problem is non-convex, meaning that each model
768 fit returns slightly different results, making it difficult to compare the output using different
769 parameters even on the same data. To speed up the model fitting process, we randomly down
770 sampled 10,000 cells. For peaks that have zero counts in these 10,000 sampled cells, instead of
771 removing them from the matrix, we further sampled cells where they have non-zero counts. This
772 ensures that we can project the fitted model to the full count matrix. In total, 10,711 cells were
773 used for the initial model fitting. To make sure we can easily compare multiple model fits on the
774 same data, we first performed NMF using a small number of total topics (k), and then fit NMF with
775 more topics conditioning on the previous model fit. We started by fitting the topic model with k=6
776 using the 'fit_topic_model' function, using 100 main iterations and 200 refining iterations
777 ('numiter.main=100, numiter.refine=200'). This returned a multinomial topic model fitting, which
778 was then projected to the full count data using the 'predict' function implemented in 'fastTopics'.
779 To fit a model with eight topics (k=8), we propagated the loading matrix and the factor matrix from
780 k=6 with two more columns of uniformly distributed values (1/k for loading matrix and 1/[number
781 of peaks] for score matrix). We then applied the fitting steps adapted from the 'fit_topic_model'
782 function. Briefly, the expanded loading matrix and factor matrix were passed into
783 'init_poisson_nmf' together with the down sampled count matrix to initialize a new Poisson model.
784 Then, the model was fitted with EM algorithm for 100 iterations (main fitting) and updated with

785 SCD algorithm for 200 iterations in two consecutive runs of the 'fit_poisson_nmf' function. The
786 fitted Poisson model was converted to a multinomial NMF model with 'poisson2multinom' function.
787 The output of this final step is a cell-by-eight-topic loading matrix. We iterated this process with
788 10, 12, 14, 16, 18 and 20 topics. This framework allowed us to keep the order of topics constant,
789 making it possible to compare across model fits, while updating them when more topics are added.
790 To visualize topic modeling results in a Structure plot, we performed PCA on the loading matrix
791 (after centering and scaling) and used the rotated data matrix for K-means clustering (K=30). To
792 avoid over-plotting, we randomly selected 2.5% of cells from each cluster, resulting in a subset of
793 ~5,500 cells for visualization.

794

795 **Calculation of gene-level scores from peak-level scores.** To define a molecular program
796 underlying each topic, we relied on the factor matrix. We selected the top 10% of peaks with the
797 highest score in each topic. To calculate gene-level scores from peak-level scores, we applied
798 ArchR's exponential-weighting strategy to calculate gene activity scores. Briefly, scores of peaks
799 within the gene body are directly summed up, and scores of peaks up to 5 Kb upstream of the
800 gene TSS are weighted by distance-based power-law. We then calculated the Z score of each
801 gene across all the topics.

802

803 **Stratified-LDSC analysis on top peaks in each topic.** For s-LDSC analysis, we selected top
804 10% peaks with the highest scores from each topic. Each peak was extended to 1,500 bp around
805 its center. We used GWAS summary statistics for 50 phenotypes (11 immune-related diseases
806 and 36 blood cell-type traits, and height as a negative control) (**Supplementary Table 13**). GWAS
807 summary statistics were munged by 'munge_sumstats.py'. LD score calculation and s-LDSC
808 analysis were carried out according to LDSC documentation conditioning on default baseline
809 annotations.

810

811 **Association between topic k17 loadings and COVID-19 status.** To test whether k17 loadings
812 are associated with COVID-19 status, we first calculated average donor-level k17 loadings for
813 each sample. We only included cells from healthy controls or active COVID-19 at the time of
814 sample collection and with k17 loading larger than 0.01, as cells below this cutoff largely represent
815 estimation noise. We then fitted two mixed-effects logistic regression models:

816 (1) $\text{logit}(\text{COVID} - 19) \sim \text{loading}_{k17} + M\text{Ratio} + n\text{Frag} + (1|\text{donor})$

817 (2) $\text{logit}(\text{COVID} - 19) \sim M\text{Ratio} + n\text{Frag} + (1|\text{donor})$

818

819 Formula (1) is the full model and (2) is the null model. We then performed a likelihood ratio test
820 (LRT) with 'anova' function in R to test whether k17 loadings significantly predicts donor COVID-
821 19 status.

822

823 **Trajectory analysis in topic model.** We defined the cell trajectory directly from topic loadings
824 with slight modifications to accommodate the analysis workflow of the ArchR package. As a proof-
825 of-concept, we first scrutinized the B cell trajectory. Since k2 represents naive B cells, its loadings
826 are the highest in naive B cells and decreases in memory B cells and plasmablast. To construct
827 a trajectory that represents B cell maturation, we used the reverse order of k2 loadings, such that
828 the trajectory value increases as naive B cells transit into memory B cells. The trajectory was

829 restricted to L1-annotated B cells, and we set the value of all other cell-types to 'NA', so that
830 ArchR does not use these cells in the analysis. The trajectory values were then scaled to the
831 range of 0-100 for downstream analysis. To study the change in the proportion of memory B cells
832 or plasmablasts along the trajectory, the trajectory was divided into percentiles, and we calculated
833 the proportion of non-naive B cells in each percentile according to L1 annotation. When building
834 a trajectory for k9, we removed cells whose k9 loadings are below 0.1, as these likely represent
835 background noise rather than biologically meaningful variations.

836
837 After deriving the trajectory values from cell loadings, we added the trajectories to the ArchR
838 project as a metadata column. To visualize the changes of gene activity scores along the
839 trajectory, we used the 'getTrajectory' function, followed by 'plotTrajectoryHeatmap' functions with
840 options 'varCutOff=0.8, returnMatrix=TRUE'. The heatmap was visualized using
841 ComplexHeatmap⁷³.

842
843 To assess the relevance of k17 trajectory to COVID-19, we first asked in a cluster-based analysis,
844 how many differentially active genes can be found between healthy and COVID-19 cells. To do
845 so, we compared all COVID-19 cells with all healthy cells in k17 trajectory regardless of k17
846 loadings using the 'getMarkerFeatures' function. We then grouped cells into quintiles according
847 to their k17 loadings, where higher quintiles were enriched for more COVID-19 cells. We next
848 tested for differential gene activity between all cells in the first quintiles and COVID-19 cells in the
849 higher quintiles (second and above). Note in this test we used healthy and COVID-19 cells in the
850 first quintile as control, following the idea that COVID-19 cells in the first quintile are epigenetically
851 similar to healthy cells.

852 853 **Chromatin accessibility QTL mapping.**

854 **RASQUAL caQTL mapping.** Chromatin accessibility QTL (caQTL) were first mapped using
855 RASQUAL on three grouping levels, whole blood-like (WB-like), L1 and L2 annotations. We
856 generated pseudobulk counts by summing single-cell counts across cell barcodes within each
857 group. For the WB-like group, we included all peaks and all individuals. For caQTL mapping in L1
858 and L2 cell-types, we only included cell-types with at least 50 cells in at least 10 individuals. From
859 the pseudobulk count table, we calculated library sizes and phenotype PCs (after scaling and
860 centering; using 'prcomp' function in R). To get allelic-specific read counts, we extracted reads
861 from each group using 'filterbarcodes' command from sinto v0.7.5 and counted allelic-specific
862 reads using 'createASVCF.sh' from RASQUAL. We only kept bi-allelic SNPs with at least four
863 minor allele counts across tested individuals. We included library size as offsets and five genotype
864 PCs, the number of cells, and the GC content for each peak as covariates. RASQUAL was run in
865 nominal mode and permutation mode. We extracted the lead SNP for each tested peak and used
866 nominal and permuted $\log_{10}(\text{q-value})$ from RASQUAL to calculate empirical p-values with
867 'empPvals' function from the 'qvalue' R package, and then derived q-values from the empirical p-
868 values. We used q-value below 0.1 as the cutoff for significant caQTLs.

869
870 **Enrichment of RASQUAL caQTLs in bulk LCL caQTLs.** To test the enrichment of RASQUAL
871 caQTLs from WB in bulk caQTLs from LCL, we obtained summary statistics from a previous
872 study²⁸. We extracted lead SNP for each peak in the LCL dataset and ranked them by their

873 significance. We then tested the enrichment of RASQUAL lead SNPs in the top 1%, 5%, and 10%
874 of the most significant LCL caQTL lead SNPs using Fisher's exact test.

875

876 **Enrichment of RASQUAL caQTLs in DICE bulk eQTLs.** To test the enrichment of RASQUAL
877 caQTLs from common immune cell types in bulk eQTLs from DICE, we first extracted the genomic
878 locations of lead eQTL SNPs and extended it by 500 bp on each side and converted it to bed
879 format. These eQTL regions form the genomic annotation in which caQTL enrichment is tested.
880 We then converted RASQUAL lead caQTL SNP positions to bed format, and tested their
881 enrichment in eQTL regions using QTLtools 'fenrich' command⁷⁴, while feeding our peak set into
882 the '--tss' argument to adjust for the fact that RASQUAL caQTLs are enriched in the cPeaks
883 themselves. The odd ratios from 'fenrich' were visualized after being normalized to the maximum
884 odd ratio in each caQTL cell type.

885

886 **Single-cell Poisson mixed-effect model (sc-PME) caQTL mapping.** Single-cell caQTL
887 mapping with the sc-PME model was first performed in three studies separately. For continuous
888 covariates, we included top five genotype PCs, top five LSI dimensions, TSS enrichment scores,
889 fraction of mitochondrial reads, log₁₀ of number of unique fragments, all of which are scaled and
890 fitted as fixed effects. We also included libraries and donors as random effects. The Poisson
891 mixed effect model was fitted using the 'glmer' function ('family=poisson') in the lme4 R package.
892 We set the additional options as 'nAGQ=0, control=glmerControl(optimizer="bobyqa",
893 calc.derivs=F)' to save computational time for model fitting. We performed meta-analysis using
894 effect sizes and standard errors from all SNPs in the three datasets and ran Metasoft without
895 genomic control. For downstream analysis, we used effect sizes and standard errors from the
896 random effects model and p-values from the Han and Eskin's Random Effects model (RE2)³⁴. To
897 call significant caQTL in the meta-analyzed sc-PME results, we first applied Bonferroni correction
898 for all SNPs in a given peak, extracted the lead SNP for each peak, and then calculated q-values
899 from the Bonferroni-adjusted p-values across all lead SNPs. We used a q-value below 0.1 as a
900 cutoff for significant lead caQTL.

901

902 **Dynamic caQTL mapping with sc-PME.** To identify dynamic effects of lead caQTL SNPs along
903 cell trajectories defined by topic modeling, we tested for interaction between genotype dosages
904 and topic loadings. To avoid confounding dynamic caQTL with cell-type specific caQTL, we (1)
905 mapped dynamic caQTLs separately in each common cell-type and (2) only included topics that
906 are present in each cell-type as follows: B (k1, k11), CD4 T (k6, k7, k17), CD8 T (k3, k6, k7, k14,
907 k17, k18, k19), NK (k3, k17), monocyte (k10, k12, k15), DC (k4, k10, k12, k15), other T cell (k3,
908 k6, k8, k14, k17, k18, k19). For each SNP, we fitted a model with genotype-by-loading interaction
909 term and a reduced model without the interaction term. We then use R function 'anova' to perform
910 a likelihood-ratio test (LRT) comparing the two models, and used p-values from LRT to call
911 significant dynamic caQTLs. Because we only tested the top caQTL SNP for every cPeak, we
912 calculated q-values from LRT p-values in each topic separately, and then multiplexed the q-value
913 by the number of topics in which a given SNP was tested for; this is equivalent to a Bonferroni
914 adjustment on the number of topics tested for each SNP, thus caQTL SNPs from cells with more
915 topics (e.g. CD8 T cells) were subjected to more stringent significant level cutoff. We reported
916 adjusted q-value below 0.01 as significant dynamic caQTLs.

917

918 **Colocalization of caQTLs with bulk eQTLs and GWAS.**

919 To perform colocalization between caQTLs and eQTLs, we used the eQTL summary statistics
920 from the DICE study we re-processed and published before¹. We tested for colocalization
921 between a caQTL and an eQTL when there are more than 150 overlapping SNPs and their
922 corresponding lead SNPs are among the overlapping SNPs.

923

924 To perform colocalization between our caQTL and in-sample COVID-19 eQTLs, we used the list
925 of significant eGenes defined as mashr³⁴ local false sign rate (lfsr) below 0.1 in the accompanying
926 manuscript (Randolph et al.). We tested for colocalization between a caQTL and an eQTL when
927 there are more than 150 overlapping SNPs and their corresponding lead SNPs are among the
928 overlapping SNPs.

929

930 To perform colocalization between caQTL and GWAS, we used GWAS summary statistics of 11
931 immune-related diseases and 36 blood cell-type GWAS that we accessed previously¹. Briefly, we
932 defined a GWAS locus as a 1 Mb window centered around a SNP with a p-value below 1e-7,
933 starting from the SNP with the smallest p-value, removing all SNP lies within 1 Mb, and iteratively
934 identified all GWAS loci until no SNPs with p-value below 1e-7 remained. Like eQTL, we tested
935 for colocalization between a caQTL and a GWAS locus when their corresponding lead SNPs are
936 among the overlapping SNPs and there are more than 150 overlapping SNPs. All colocalization
937 analyses were performed with the 'coloc.abf' function from R package 'coloc' v5.2.1³⁰.

938 **Acknowledgements**

939 We thank N. Gonzales for her careful reading of our manuscript and their insightful
940 comments. This work was completed in part with resources provided by the University of
941 Chicago Research Computing Center. This work was supported by National Institute of Health
942 grants R35GM153249 (Y.I.L.), R01GM130738 (Z.M., Y.I.L.), R01GM134376 (L.B.B.) and
943 R35GM152227 (L.B.B.). This work was also supported by Canadian Institutes of Health
944 Research grants VR2-173203 and 178344 to D.E.K. We also acknowledge the support from the
945 UChicago DDRCC, Center for Interdisciplinary Study of Inflammatory Intestinal Disorders(C-IID)
946 (NIDDK P30 DK042086). H.E.R. was supported by a Ruth L. Kirschstein National Research
947 Service Award (NHLBI F31-HL156419). The Biobanque Québécoise de la COVID-19 (BQC19)
948 is supported by the FRQS Génome Québec and the Public Health Agency of Canada. L.B.B.
949 and Y.I.L. are CZ Biohub Investigators.

950 **Author contributions**


951

952 Y.I.L. and L.B.B. jointly supervised research. Z.M., Y.I.L., and L.B.B. conceived and designed the
953 experiments. H.E.R., E.K., A.D., V.L., C.B, D.E.K performed the experiments. Z.M. performed
954 statistical analyses and analyzed the data. H.E.R. and R.A.-G. also performed data analysis.
955 Z.M. and Y.I.L. wrote the paper with critical contributions from L.B.B. and X.L. and input from all
956 authors.

957

958 **Competing interests**


959 The authors declare no competing interests.



960
961
962
963
964
965
966
967
968
969


Fig. 1. An integrated map of scATAC-seq of PBMC from 20 donors with active COVID-19, 19 COVID-19 convalescent donors and 20 healthy controls. a, Schematic representation of sample collection, data integration and analysis workflow. (Some icons are from bioicons.com). **b**, A UMAP embedding of all cells from three integrated studies, colored by Azimuth L1 annotation of seven common immune cell-types. **c**, The same UMAP embedding as in **b**, colored by 21 immune cell-types and subtypes in Azimuth L2 annotation. **d**, Gene activity scores of marker genes in the seven common immune cell-types. Scores were imputed with MAGIC for visualization purposes. **e**, Heatmap for marker genes for cell subtypes in L2 annotation. **f**, Color-coded genome browser tracks of aggregated scATAC-seq reads in genomic loci around marker

970 genes. Shaded regions highlight cell-type-specific chromatin accessibility regions. **g**, Estimates
971 of cell-type compositions in L1 annotation for all samples. Samples are clustered by distances in
972 scaled cell-type compositions. **h**, Comparison of imputation quality (INFO) score from low-pass
973 WGS using GLIMPSE, aggregated scATAC-seq reads using GLIMPSE, and DNA microarray
974 using Minimac4 stratified by reference MAF bins.




975
 976 **Fig. 2. Topic modeling helps interpretation of inter-cellular and inter-individual variation in**
 977 **scATAC-seq profiles.** **a**, Structure plots of topic loadings in 2,000 randomly selected cells when
 978 fitting 6, 10, 14 and 20 topics. Cells were grouped by seven common immune cell-types to
 979 highlight coarse-grained differences in topic loading among cell-types. **b**, Heatmap showing the
 980 average loading for each topic in each cell-type in L2 annotation. **c**, Heatmap of Z-score
 981 normalized gene-level scores calculated from peak-level scores in each topic. **d**, Top, smoothed
 982 percentage of non-naïve B cells in trajectory percentile. Heatmap on the left shows the Spearman
 983 correlation between gene-activity (GA) scores and memory B cell trajectory; heatmap on the right
 984 shows row-normalized GA score changing along the trajectory. **e**, Heritability enrichment of 50
 985 GWAS using peaks with the highest 10% of scores in each topic. Dashed boxes highlight specific
 986 enrichment results discussed in the main text. **f**, Similar to **d**, showing the trajectory and relevant
 987 genes in COVID19-associated topic k17. **g**, Genome browser tracks of the genomic region around
 988 three genes (*PRG4*, *CCL3* and *CCR2*) that progressively gained or lost accessibility along k17
 989 trajectory. Cells are grouped by disease status and k17 quintiles.

990




991
 992 **Fig. 3. Mapping of caQTL with RASQUAL and sc-PME model.** **a**, Scatter plot comparing the
 993 number of RASQUAL caQTL as a function of cell number and sample size in this study and two
 994 other published scATAC-seq caQTL studies. **b**, RASQUAL effect sizes in our merged data and
 995 Benaglio et al. data are highly correlated. Novel caQTLs found in merged data show allelic
 996 imbalance in Benaglio et al., albeit with smaller effect sizes. **c**, RASQUAL caQTLs in whole blood
 997 are enriched in bulk caQTLs from LCL for all significant ones (left) and only novel ones found in
 998 our merged data (right). **d**, Heatmap showing cell-type-specific enrichment of caQTLs in DICE

999 eQTLs. Odd ratios are normalized by the maximum value in each row. **e**, QQ-plot of RASQUAL
1000 caQTLs in DICE eQTLs. Top: caQTLs in B cells show elevated signals only in eQTLs from B cells
1001 in DICE; bottom: caQTLs in monocytes show elevated signals only in eQTLs from classical and
1002 non-classical monocytes in DICE. All other DICE cell-types were colored grey. **f**, RASQUAL and
1003 sc-PME caQTLs have highly correlated and concordance effect sizes. Results from monocytes
1004 are used as an example here. **g**, Replication of RASQUAL caQTL in sc-PME model in seven
1005 common immune cell-types. Barplot shows the number of RASQUAL caQTLs that are replicated
1006 or not in sc-PME model; line chart shows the percentage of RASQUAL caQTLs replicated. **h**, An
1007 example of a DICE eQTL to gene *ANTXR1P1* in monocytes colocalizing with sc-PME caQTL but
1008 is different from the RASQUAL lead SNP. Vertical dashed lines highlight the genomic
1009 coordinations of lead SNPs in RASQUAL, sc-PME and DICE. The shaded region highlights the
1010 mapping window of RASQUAL and its position relative to the mapping window of sc-PME. SNPs
1011 are colored by LD to the lead SNP. **i**, Number of dynamic caQTLs in each cell-type along relevant
1012 trajectories defined by topic loadings. **j**, left: Z scores of dynamic and non-dynamic caQTLs from
1013 CD8 T cells in rolling windows along topic k17 trajectory. Dynamic caQTLs were further
1014 categorized by whether they are consistently active along k17 trajectory or only in part of the
1015 trajectory. The most significant 50 caQTLs from each category were plotted. Right: effect sizes of
1016 one representative dynamic caQTL.
1017




1018
 1019 **Fig. 4. caQTL-eQTL colocalization and dynamic caQTL mapping.** **a**, Sharing of caQTLs in sc-
 1020 PME model in five common immune cell-types. **b**, Comparison of caQTL sharing of caQTLs in
 1021 seven immune cell-types for RASQUAL and sc-PME model. Top: bar plot of number of caQTLs
 1022 shared in a given number of contexts. Bottom: \log_2 fold-change in the number of caQTLs between
 1023 sc-PME and RASQUAL, highlighting the increased level of sharing for sc-PME caQTLs. **c**, Barplot
 1024 for the number (top) and proportion (bottom) of caQTLs that colocalize with eQTL from DICE and
 1025 our in-sample accompanying eQTL data. **d**, Logistic regression coefficients and 95% confidence
 1026 intervals for variables that predict caQTL-eQTL colocalization. Model includes all caQTL-eQTL
 1027 pairs that colocalize in at least one cell-type. **e**, Top: heatmap for COLOC PP4 of shared caQTLs
 1028 between CD8 T cells and monocytes. Bottom: example Manhattan plots for shared caQTL
 1029 colocalizing with cell-type specific eQTLs in monocytes and CD8 T cells, respectively. **f**, TF motif
 1030 enrichment in peaks whose caQTL colocalize with eQTL in CD8 T cells and monocytes
 1031 specifically, or in both cell-types. Colored points represent TFs with adjusted enrichment p-values

1032 below 0.05. **g**, TF motifs enriched in non-COLOC peaks in CD8 T cells specifically show higher
1033 deviation Z scores in CD8 TEM in our scATAC data.
1034




1035
 1036 **Fig. 5. Widespread sharing of caQTLs impedes functional interpretation of disease GWAS.**
 1037 **a**, Scatter plot for the percentage of colocalized GWAS loci with eQTL in DICE and caQTL. **b**,
 1038 The proportion of caQTL peaks colocalizing with GWAS, categorized by all peaks, dynamic, cell-
 1039 type specific and shared peaks in each of the five cell-types. **c**, The number of caQTL peaks
 1040 colocalizing with GWAS, categorized by all peaks, dynamic, cell-type specific and shared peaks
 1041 in each of the five cell-types. Schematic showing that restricting eQTL-GWAS COLOC by caQTL-
 1042 GWAS COLOC in the same context to better nominate causal genes and contexts. **d**,
 1043 Characterization of colocalized GWAS loci by the number of contexts in which they colocalize
 1044 with either eQTL, caQTL or both. **f**, Forest plot showing that restricting eQTL-GWAS pairs to
 1045 contexts also supported by caQTL-GWAS COLOC increases enrichment in causal S2G (cS2G)
 1046 links. Error bars represent 95% confidence intervals of $\log_2(\text{OR})$ estimates. **g**, An example
 1047 showing that eQTL- and caQTL-GWAS COLOC together narrows down *CARD9* gene in
 1048 monocytes as the causal gene and context for an IBD locus. Top: genome browser tracks showing
 1049 chromatin accessibility around *CARD9* locus. Bottom: Manhattan plots for IBD GWAS, colocalized
 1050 caQTL and eQTLs in various cell-types. Dashed lines highlight the position of lead SNPs in GWAS
 1051 and the QTL data. Colored box highlights the nominated causal eQTL.



1052
1053
1054
1055
1056


Extended Data Fig. 1. Quality control on scATAC-seq data and genotyping. a, UMAP of integrated 36 samples collected in this study. b, Violin plots showing the distribution of common quality control metrics for all cells in the three datasets. c, Confusion matrix comparing Azimuth L2 annotation and cell clusters. Heatmap is colored by row normalized proportions, such that the

1057 cell-type compositions sum up to one on each row. **d**, Bar plots showing expansion of memory B
1058 cells and plasmablasts (highlighted in border) in a group of COVID-19 samples. **e**, The three
1059 scATAC-seq data sets used in this study have very similar read coverages at 10,000 randomly
1060 sampled positions genome-wide. **f**, Number of 1000G SNPs covered by at least one, two or three
1061 reads in each single cell as a function of the number of unique fragments. Dashed line indicates
1062 1,000 unique fragments, the cutoff we used for filtering low-quality cells. **g**, Mean correlation
1063 between GLIMPSE-imputed genotype dosages from aggregated scATAC-seq reads and those
1064 imputed from microarray data using Minimac4. **h**, PCA analysis of all individuals in this study with
1065 1000G samples.




1066
1067
1068
1069
1070

Extended Data Fig. 2. Visualization of cell loadings for the 20 topics in UMAP embedding. UMAP plots showing the distribution and quantity of loadings for the 20 topics. Loading scores are normalized by min-max for each topic, and loading scores below 0.05 in a cell were set to 0 for visualization purposes (gray).




1071
 1072 **Extended Data Fig. 3. Topic modeling analysis.** **a**, Scatter plot showing the correlation between
 1073 k2 loadings and TSS Enrichment scores. **b**, Bar plot showing the genomic annotation of the top
 1074 3,000 peaks in each topic, compared to all peaks, highlighting the over-representation of
 1075 promoters in k2. **c**, Top: schematic showing the four strategies to calculate gene-level score from
 1076 peak-level scores in topic analysis. Bottom: gene-level scores calculated from the four strategies
 1077 for peaks in topic k7, which is a naive T cell topic. **d**, GO Biological Process pathways enriched
 1078 in top 1,500 scored genes for each topic. **e**, Heatmap of adjusted p-values for TF motif enrichment
 1079 in top 3,000 peaks in each topic. $-\log_{10}(P \text{ adj.})$ values are normalized relative to maximum for each
 1080 TF across all topics. Top five enriched TFs are shown for each topic. **f**, The number of differentially
 1081 active genes in COVID-19 cells in the top 4 k17 quintiles compared to all cells in the first k17
 1082 quintiles, plotted together with the number of differentially active genes when all COVID-19 cells
 1083 in k17 were tested against all healthy cells in k17. **g**, GO Biological Process pathways enriched
 1084 in up-regulated genes from groups in **f**. Only groups with significantly enriched GO terms are
 1085 plotted.
 1086



1087
 1088 **Extended Data Fig. 4. CaQTL mapping using RASQUAL and sc-PME model in harmonized**
 1089 **data. a**, Principal component analysis (PCA) on pseudobulk count data for WB and six cell-types
 1090 in which caQTL mapping was conducted. Each sample is colored by study. **b**, QQ-plot showing
 1091 the enrichment of caQTLs in our accompanying COVID-19 eQTLs for all eQTLs (left) and

1092 conditioning on only significant eQTLs (right). For each cell type in our study, we extracted and
1093 plotted eQTLs p-values from all cell types, highlighting matched cell types in colored dots; eQTL
1094 p-values from the remaining cell types were colored grey. When all genes are used, caQTLs tend
1095 not to have the highest enrichment in eQTLs in corresponding cell types, except for CD4 T and
1096 monocyte, due to lower power in the eQTL data (left). We therefore conditioned on only significant
1097 eGenes in each cell type to mitigate the differences in power between cell types, and observed
1098 larger enrichment of caQTL in eQTLs for matched cell types (right). **c**, Histogram showing
1099 distances from peak centers to significant lead caQTL in monocytes from RASQUAL (top) and
1100 sc-PME (bottom). Green shaded region highlights peak size (500 bp); blue shaded region
1101 highlights RASQUAL mapping window (10 Kb) relative to sc-PME mapping window (250 Kb). **d**,
1102 Scatter plots comparing RASQUAL effect sizes (P_i) with sc-lme effect sizes (left) and sc-PME
1103 effect sizes (right). Only significant RASQUAL caQTLs on chromosome 1 in monocytes were
1104 plotted. **e**, Top pathways enriched in genes linked to peaks with k17-interacting dynamic caQTLs
1105 in CD8 T cells.
1106



1107

1108

1109

1110

1111

1112

1113

1114


1115

1116

1117

1118

Extended Data Fig. 5. a, Table summarizing the mapping of 15 immune cell-types in DICE data to the seven common cell-types used in caQTL mapping. **b**, Manhattan plots for RA GWAS locus (7:99893148) and colocalized caQTLs (chr7:99818835–99819335) and eQTLs (*PVRIG*), with genome browser tracks for scATAC data in CD4 T cells. **c**, Manhattan plots for an RA GWAS locus near TSS of *RPS26*; the GWAS locus colocalized with *RPS26* eQTLs in DICE. The TSS peak is accessible and has caQTL in all five cell types, but the caQTLs do not colocalize with the RA GWAS. **d**, Manhattan plots for RA, CD, UC, MS GWAS loci and colocalized cPeak (chr14:69262828–69263328). Genome browser track shows promoter region of *ZFP36L1* near the colocalized peak and scATAC data in CD4 T cells. **e**, Manhattan plots for RA GWAS locus (22:37316259) and colocalized cPeak (chr22:37256806–37257306) in NK cells in the *NCF4* locus. Genome browser track shows scATAC data in NK cells in the same region.



1119
1120
1121
1122
1123
1124
1125

Extended Data Fig. 6. a, Boxplot showing the number of colocalized peaks for each GWAS locus as a function of the number of contexts where colocalization is detected. **b,** Boxplot showing the number of colocalized genes in DICE for each GWAS locus as a function of the number of contexts where colocalization is detected. The 15 DICE cell-types and subtypes were mapped to 5 common immune cell-types.

1126 References

- 1127 1. Mu, Z. *et al.* The impact of cell type and context-dependent regulatory variants on human
1128 immune traits. *Genome Biol.* **22**, 122 (2021).
- 1129 2. Mostafavi, H., Spence, J. P., Naqvi, S. & Pritchard, J. K. Systematic differences in
1130 discovery of genetic effects on gene expression and complex traits. *Nat. Genet.* 1–10
1131 (2023).
- 1132 3. Yao, D. W., O'Connor, L. J., Price, A. L. & Gusev, A. Quantifying genetic effects on disease
1133 mediated by assayed gene expression levels. *Nat. Genet.* **52**, 626–633 (2020).
- 1134 4. Strober, B. J. *et al.* Dynamic genetic regulation of gene expression during cellular
1135 differentiation. *Science* **364**, 1287–1290 (2019).
- 1136 5. Aracena, K. A. *et al.* Epigenetic variation impacts individual differences in the transcriptional
1137 response to influenza infection. *Nature Genetics* 1–12 (2024).
- 1138 6. Baca, S. C. *et al.* Genetic determinants of chromatin reveal prostate cancer risk mediated
1139 by context-dependent gene regulation. *Nat. Genet.* (2022) doi:10.1038/s41588-022-01168-
1140 y.
- 1141 7. Hormozdiari, F. *et al.* Leveraging molecular quantitative trait loci to understand the genetic
1142 architecture of diseases and complex traits. *Nat. Genet.* **50**, 1041–1047 (2018).
- 1143 8. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide
1144 association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).
- 1145 9. Benaglio, P. *et al.* Mapping genetic effects on cell type-specific chromatin accessibility and
1146 annotating complex immune trait variants using single nucleus ATAC-seq in peripheral
1147 blood. *PLoS Genet.* **19**, e1010759 (2023).
- 1148 10. You, M. *et al.* Single-cell epigenomic landscape of peripheral immune cells reveals
1149 establishment of trained immunity in individuals convalescing from COVID-19. *Nat. Cell*
1150 *Biol.* **23**, 620–630 (2021).

- 1151 11. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587.e29
1152 (2021).
- 1153 12. Stephenson, E. *et al.* Single-cell multi-omics analysis of the immune response in COVID-
1154 19. *Nat. Med.* **27**, 904–916 (2021).
- 1155 13. Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* **9**, R137 (2008).
- 1156 14. Cheong, J.-G. *et al.* Epigenetic memory of coronavirus infection in innate immune cells and
1157 their progenitors. *Cell* (2023) doi:10.1016/j.cell.2023.07.019.
- 1158 15. Rubinacci, S., Ribeiro, D. M., Hofmeister, R. J. & Delaneau, O. Efficient phasing and
1159 imputation of low-coverage sequencing data using large reference panels. *Nat. Genet.* **53**,
1160 120–126 (2021).
- 1161 16. Bravo González-Blas, C. *et al.* cisTopic: cis-regulatory topic modeling on single-cell ATAC-
1162 seq data. *Nat. Methods* **16**, 397–400 (2019).
- 1163 17. Kotliar, D. *et al.* Reproducible single cell annotation of programs underlying T-cell subsets,
1164 activation states, and functions. *bioRxivorg* (2024) doi:10.1101/2024.05.03.592310.
- 1165 18. Carbonetto, P. *et al.* Interpreting structure in sequence count data with differential
1166 expression analysis allowing for grades of membership. *bioRxiv* 2023.03.03.531029 (2023)
1167 doi:10.1101/2023.03.03.531029.
- 1168 19. Carbonetto, P., Sarkar, A., Wang, Z. & Stephens, M. Non-negative matrix factorization
1169 algorithms greatly improve topic model fits. *arXiv [stat.ML]* (2021).
- 1170 20. Granja, J. M. *et al.* ArchR is a scalable software package for integrative single-cell
1171 chromatin accessibility analysis. *Nat. Genet.* **53**, 403–411 (2021).
- 1172 21. Reshef, Y. A. *et al.* Co-varying neighborhood analysis identifies cell populations associated
1173 with phenotypes of interest from single-cell transcriptomics. *Nat. Biotechnol.* (2021)
1174 doi:10.1038/s41587-021-01066-4.

- 1175 22. Dann, E., Henderson, N. C., Teichmann, S. A., Morgan, M. D. & Marioni, J. C. Differential
1176 abundance testing on single-cell data using k-nearest neighbor graphs. *Nat. Biotechnol.*
1177 (2021) doi:10.1038/s41587-021-01033-z.
- 1178 23. Lipsky, P. E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity.
1179 *Nat. Immunol.* **2**, 764–766 (2001).
- 1180 24. Caielli, S., Wan, Z. & Pascual, V. Systemic Lupus Erythematosus Pathogenesis: Interferon
1181 and Beyond. *Annu. Rev. Immunol.* (2023) doi:10.1146/annurev-immunol-101921-042422.
- 1182 25. Blangy-Letheule, A. *et al.* Value of a secretomic approach for distinguishing patients with
1183 COVID-19 viral pneumonia among patients with respiratory distress admitted to intensive
1184 care unit. *J. Med. Virol.* **96**, e29756 (2024).
- 1185 26. Coperchini, F. *et al.* The cytokine storm in COVID-19: Further advances in our
1186 understanding the role of specific chemokines involved. *Cytokine Growth Factor Rev.* **58**,
1187 82–91 (2021).
- 1188 27. Cuomo, A. S. E. *et al.* Single-cell RNA-sequencing of differentiating iPS cells reveals
1189 dynamic genetic effects on gene expression. *Nat. Commun.* **11**, 810 (2020).
- 1190 28. Turner, A. W. *et al.* Single-nucleus chromatin accessibility profiling highlights regulatory
1191 mechanisms of coronary artery disease risk. *Nat. Genet.* 1–13 (2022).
- 1192 29. Kumasaka, N., Knights, A. J. & Gaffney, D. J. High-resolution genetic mapping of putative
1193 causal interactions between regions of open chromatin. *Nat. Genet.* **51**, 128–137 (2019).
- 1194 30. Schmiedel, B. J. *et al.* Impact of Genetic Polymorphisms on Human Immune Cell Gene
1195 Expression. *Cell* **175**, 1701-1715.e16 (2018).
- 1196 31. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
1197 association studies using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).
- 1198 32. Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association
1199 studies. *Nat. Genet.* **48**, 245–252 (2016).

- 1200 33. Gamazon, E. R. *et al.* A gene-based association method for mapping traits using reference
1201 transcriptome data. *Nat. Genet.* **47**, 1091–1098 (2015).
- 1202 34. Uribut, S. M., Wang, G., Carbonetto, P. & Stephens, M. Flexible statistical methods for
1203 estimating and testing effects in genomic studies with multiple conditions. *Nat. Genet.* **51**,
1204 187–195 (2019).
- 1205 35. Han, B. & Eskin, E. Random-effects model aimed at discovering associations in meta-
1206 analysis of genome-wide association studies. *Am. J. Hum. Genet.* **88**, 586–598 (2011).
- 1207 36. Nathan, A. *et al.* Single-cell eQTL models reveal dynamic T cell state dependence of
1208 disease loci. *Nature* 2021.07.29.454316 (2022).
- 1209 37. Yazar, S. *et al.* Single-cell eQTL mapping identifies cell type–specific genetic control of
1210 autoimmune disease. *Science* **376**, eabf3041 (2022).
- 1211 38. Randolph, H. E. *et al.* Genetic ancestry effects on the response to viral infection are
1212 pervasive but cell type specific. *Science* **374**, 1127–1133 (2021).
- 1213 39. Banovich, N. E. *et al.* Impact of regulatory variation across human iPSCs and differentiated
1214 cells. *Genome Res.* **28**, 122–131 (2018).
- 1215 40. Natri, H. M. *et al.* Cell-type-specific and disease-associated expression quantitative trait loci
1216 in the human lung. *Nat. Genet.* **56**, 595–604 (2024).
- 1217 41. Nasser, J. *et al.* Genome-wide enhancer maps link risk variants to disease genes. *Nature*
1218 **593**, 238–243 (2021).
- 1219 42. Cruz-Guilloty, F. *et al.* Runx3 and T-box proteins cooperate to establish the transcriptional
1220 program of effector CTLs. *J. Exp. Med.* **206**, 51–59 (2009).
- 1221 43. Wang, D. *et al.* The transcription factor Runx3 establishes chromatin accessibility of cis-
1222 regulatory landscapes that drive memory cytotoxic T lymphocyte formation. *Immunity* **48**,
1223 659-674.e6 (2018).
- 1224 44. McLane, L. M. *et al.* Role of nuclear localization in the regulation and function of T-bet and
1225 Eomes in exhausted CD8 T cells. *Cell Rep.* **35**, 109120 (2021).

- 1226 45. Alasoo, K. *et al.* Shared genetic effects on chromatin and gene expression indicate a role
1227 for enhancer priming in immune response. *Nat. Genet.* **50**, 424–431 (2018).
- 1228 46. Ishigaki, K. *et al.* Multi-ancestry genome-wide association analyses identify novel genetic
1229 mechanisms in rheumatoid arthritis. *Nature Genetics* 1–12 (2022).
- 1230 47. Zhu, Y. *et al.* Identification of CD112R as a novel checkpoint for human T cells. *J. Exp.*
1231 *Med.* **213**, 167–176 (2016).
- 1232 48. Fair, B. *et al.* Global impact of unproductive splicing on human gene expression. *Nat.*
1233 *Genet.* **56**, 1851–1861 (2024).
- 1234 49. Liu, H. *et al.* Epigenomic and transcriptomic analyses define core cell types, genes and
1235 targetable mechanisms for kidney disease. *Nat. Genet.* 1–13 (2022).
- 1236 50. Galloway, A. *et al.* RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence.
1237 *Science* **352**, 453–459 (2016).
- 1238 51. Hodson, D. J. *et al.* Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to
1239 perturbed thymic development and T lymphoblastic leukemia. *Nat. Immunol.* **11**, 717–724
1240 (2010).
- 1241 52. Son, Y.-O., Kim, H.-E., Choi, W.-S., Chun, C.-H. & Chun, J.-S. RNA-binding protein
1242 ZFP36L1 regulates osteoarthritis by modulating members of the heat shock protein 70
1243 family. *Nat. Commun.* **10**, 77 (2019).
- 1244 53. Olsson, L. M. *et al.* A case-control study of rheumatoid arthritis identifies an associated
1245 single nucleotide polymorphism in the NCF4 gene, supporting a role for the NADPH-
1246 oxidase complex in autoimmunity. *Arthritis Res. Ther.* **9**, R98 (2007).
- 1247 54. Wysocki, T. *et al.* Gene expression analysis of anti-TNF-treated rheumatoid arthritis
1248 patients reveals the links between NADPH oxidase expression profile and
1249 immunophenotypic changes in peripheral blood mononuclear cells. *Research Square*
1250 (2024) doi:10.21203/rs.3.rs-4006503/v1.

- 1251 55. Li, L. *et al.* NCF4 attenuates colorectal cancer progression by modulating inflammasome
1252 activation and immune surveillance. *Nat. Commun.* **15**, 5170 (2024).
- 1253 56. Gazal, S. *et al.* Combining SNP-to-gene linking strategies to identify disease genes and
1254 assess disease omnigenicity. *Nat. Genet.* 1–10 (2022).
- 1255 57. Zhernakova, A. *et al.* Genetic analysis of innate immunity in Crohn’s disease and ulcerative
1256 colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. *Am. J. Hum. Genet.*
1257 **82**, 1202–1210 (2008).
- 1258 58. Luo, P., Yang, Z., Chen, B. & Zhong, X. The multifaceted role of CARD9 in inflammatory
1259 bowel disease. *J. Cell. Mol. Med.* **24**, 34–39 (2020).
- 1260 59. Rivas, M. A. *et al.* Deep resequencing of GWAS loci identifies independent rare variants
1261 associated with inflammatory bowel disease. *Nat. Genet.* **43**, 1066–1073 (2011).
- 1262 60. Zhou, W. *et al.* Efficient and accurate mixed model association tool for single-cell eQTL
1263 analysis. *bioRxiv* 2024.05.15.24307317 (2024) doi:10.1101/2024.05.15.24307317.
- 1264 61. Aguet, F. *et al.* Molecular quantitative trait loci. *Nature Reviews Methods Primers* **3**, 1–22
1265 (2023).
- 1266 62. Weinand, K. *et al.* The chromatin landscape of pathogenic transcriptional cell states in
1267 rheumatoid arthritis. *Nat. Commun.* **15**, 4650 (2024).
- 1268 63. Raychaudhuri, S. *et al.* Modeling heterogeneity in single-cell perturbation states enhances
1269 detection of response eQTLs. *bioRxiv* 2024.02.20.581100 (2024)
1270 doi:10.1101/2024.02.20.581100.
- 1271 64. Xiao, Q. *et al.* Immunosuppression causes dynamic changes in expression QTLs in
1272 psoriatic skin. *Nat. Commun.* **14**, 6268 (2023).
- 1273 65. Umans, B. D. & Gilad, Y. Oxygen-induced stress reveals context-specific gene regulatory
1274 effects in human brain organoids. *bioRxiv* (2024) doi:10.1101/2024.09.03.611030.

- 1275 66. Popp, J. M. *et al.* Cell-type and dynamic state govern genetic regulation of gene expression
1276 in heterogeneous differentiating cultures. *bioRxiv* 2024.05.02.592174 (2024)
1277 doi:10.1101/2024.05.02.592174.
- 1278 67. van de Geijn, B., McVicker, G., Gilad, Y. & Pritchard, J. K. WASP: allele-specific software
1279 for robust molecular quantitative trait locus discovery. *Nat. Methods* **12**, 1061–1063 (2015).
- 1280 68. Thibodeau, A. *et al.* AMULET: a novel read count-based method for effective multipler
1281 detection from single nucleus ATAC-seq data. *Genome Biol.* **22**, 252 (2021).
- 1282 69. Haghverdi, L., Lun, A. T. L., Morgan, M. D. & Marioni, J. C. Batch effects in single-cell RNA-
1283 sequencing data are corrected by matching mutual nearest neighbors. *Nat. Biotechnol.* **36**,
1284 421–427 (2018).
- 1285 70. Ramírez, F. *et al.* deepTools2: a next generation web server for deep-sequencing data
1286 analysis. *Nucleic acids research* **44**, W160–W165 (2016).
- 1287 71. Loh, P.-R. *et al.* Reference-based phasing using the Haplotype Reference Consortium
1288 panel. *Nat. Genet.* **48**, 1443–1448 (2016).
- 1289 72. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* **48**,
1290 1284–1287 (2016).
- 1291 73. Gu, Z. Complex heatmap visualization. *Imeta* **1**, (2022).
- 1292 74. Delaneau, O. *et al.* A complete tool set for molecular QTL discovery and analysis. *Nat.*
1293 *Commun.* **8**, 15452 (2017).